var title_f37_18_38176="C2 pedicle fracture";
var content_f37_18_38176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pedicle fracture of C2 (axis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38176=[""].join("\n");
var outline_f37_18_38176=null;
var title_f37_18_38177="Hemorrhagic ovarian cyst";
var content_f37_18_38177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hemorrhagic ovarian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound image in a 38 year old female shows a complex ovarian cyst (cursors) that contains a reticular pattern of internal echoes. This appearance is classic for a hemorrhagic ovarian cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesty of Dr. Douglas Brown.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38177=[""].join("\n");
var outline_f37_18_38177=null;
var title_f37_18_38178="Vespula sting anchoring";
var content_f37_18_38178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vespula sting anchoring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38178=[""].join("\n");
var outline_f37_18_38178=null;
var title_f37_18_38179="Neomycin, polymyxin B, and hydrocortisone: Pediatric drug information";
var content_f37_18_38179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and hydrocortisone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/42/24228?source=see_link\">",
"    see \"Neomycin, polymyxin B, and hydrocortisone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/38/12901?source=see_link\">",
"    see \"Neomycin, polymyxin B, and hydrocortisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cortisporin&reg;;",
"     </li>",
"     <li>",
"      Cortomycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortimyxin&reg;;",
"     </li>",
"     <li>",
"      Cortisporin&reg; Otic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibacterial, Otic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Otic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Otic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/42/24228?source=see_link\">",
"      see \"Neomycin, polymyxin B, and hydrocortisone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic preparations (solution and suspension):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 3 drops into affected ear 3-4 times/day for up to 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 4 drops into affected ear 3-4 times/day for up to 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical cream: Children and Adults: Apply thin layer to affected area 2-4 times/day for up to 7 days. Therapy should be discontinued when control is achieved or after a week; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic suspension: Children and Adults: Instill 1-2 drops in the affected eye every 3-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortisporin&reg;: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone acetate 5 mg per g (7.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortisporin&reg;: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortomycin: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains potassium metabisulfate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (7.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, otic: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortomycin: Neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per 1 mL (10 mL) [contains thimerosal]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes topical cream",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake ophthalmic and otic suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Avoid contamination of the tip of the eye dropper; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Drops can be instilled directly into the affected ear, or a cotton wick may be saturated with suspension and inserted in ear canal. Keep wick moist with suspension every 4 hours; wick should be replaced every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply a thin layer to the cleansed, dry affected area",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid-responsive inflammatory condition for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists (Otic preparations: FDA approved in ages 2-16 years and adults; Topical cream, ophthalmic suspension: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F200667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For additional information, see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic ointment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Delayed wound healing, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataracts, corneal thinning, glaucoma, irritation, keratitis (bacterial), intraocular pressure increase, optic nerve damage, scleral thinning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (including anaphylaxis), secondary infection, sensitization to kanamycin, paromomycin, streptomycin, and gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Otic solution and suspension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic contact dermatitis, burning skin, dryness, folliculitis, hypertrichosis, hypopigmentation, irritation, maceration of skin, miliaria, ocular hypertension, perioral dermatitis, pruritus, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Burning, ototoxicity, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (including anaphylaxis), secondary infection, sensitization to karamycin, paromycin, streptomycin, and gentamicin",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrocortisone, polymyxin B sulfate, neomycin sulfate, or any component; not for use in viral infections, fungal diseases, mycobacterial infections; perforated tympanic membrane",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with chronic otitis media; use caution in glaucoma; avoid use following ocular cataract surgery; inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neomycin may cause cutaneous and conjunctival sensitization presenting as itching, reddening, edema, and failure to heal; neomycin may cause permanent hearing loss; risk of ototoxicity is increased in patients with extended use; limit therapy to 10 days; do not use in tympanic perforation. Systemic absorption of hydrocortisone may cause HPA axis suppression which can lead to adrenal crisis; risk is increased when used over large surface areas, for prolonged periods, or with occlusive dressings; children are more susceptible to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines; prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. The ophthalmic suspension should never be directly introduced into the anterior chamber; may delay corneal healing; prolonged use may result in ocular hypertension/glaucoma, optic nerve damage, cataract formation, visual field or acuity defects, and corneal and scleral thinning potentially resulting in perforation; may mask or worsen ophthalmic infection; otic solution contains potassium metabisulfate which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11414179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If ophthalmic suspension  is used &gt;10 days or in patients with glaucoma, monitor intraocular pressure (IOP).",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/38/12901?source=see_link\">",
"      see \"Neomycin, polymyxin B, and hydrocortisone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: May cause sensitivity to bright light; may cause temporary blurring of vision or stinging following administration",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Otic",
"     <b>",
"      suspension",
"     </b>",
"     is the preferred otic preparation; otic",
"     <b>",
"      suspension",
"     </b>",
"     can be used for the treatment of infections of mastoidectomy and fenestration cavities caused by susceptible organisms; otic",
"     <b>",
"      solution",
"     </b>",
"     is used",
"     <b>",
"      only",
"     </b>",
"     for superficial infections of the external auditory canal (ie, swimmer's ear)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12636 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-0C50FA751B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38179=[""].join("\n");
var outline_f37_18_38179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200652\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200653\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048905\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048901\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200644\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200632\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048908\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048907\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200667\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048910\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048900\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048899\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200660\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200639\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200640\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287265\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11414179\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048904\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048911\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/42/24228?source=related_link\">",
"      Neomycin, polymyxin B, and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/38/12901?source=related_link\">",
"      Neomycin, polymyxin B, and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_18_38180="Brompheniramine and pseudoephedrine: Patient drug information";
var content_f37_18_38180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brompheniramine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36645?source=see_link\">",
"     see \"Brompheniramine and pseudoephedrine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15909?source=see_link\">",
"     see \"Brompheniramine and pseudoephedrine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brotapp [OTC];",
"     </li>",
"     <li>",
"      J-Tan D PD [OTC];",
"     </li>",
"     <li>",
"      Lodrane&reg; D [OTC];",
"     </li>",
"     <li>",
"      LoHist PSB [OTC];",
"     </li>",
"     <li>",
"      Q-Tapp Cold &amp; Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brompheniramine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11461 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38180=[""].join("\n");
var outline_f37_18_38180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142680\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011629\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011631\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011630\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011635\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011636\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011638\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011633\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011634\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011639\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011640\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36645?source=related_link\">",
"      Brompheniramine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15909?source=related_link\">",
"      Brompheniramine and pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_18_38181="Doppler US vein";
var content_f37_18_38181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler waveform of the brachial vein with and without a tourniquet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal ultrasound images of the right arm with color and spectral Doppler shows normal venous waveforms in the brachial vein. The artery (deep to the vein) is the same color as the vein due to arterial pulsatility and the portion of the cardiac cycle captured. A) Without tourniquet, there is mild pulsality in the venous waveform reflecting right atrial pressures, but no sharp upstroke. B) When a tourniquet is applied, the waveform becomes flat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lauren W Averill, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38181=[""].join("\n");
var outline_f37_18_38181=null;
var title_f37_18_38182="Procainamide: Pediatric drug information";
var content_f37_18_38182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Procainamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"    see \"Procainamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/45/4820?source=see_link\">",
"    see \"Procainamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Procainamide&reg;;",
"     </li>",
"     <li>",
"      Procainamide Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Procan SR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class I-A",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be titrated to patient's response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Loading dose: 7-10 mg/kg infused over 60 minutes followed by a continuous I.V. infusion of  20-80 mcg/kg/minute; a retrospective study of 20 neonates (GA: &ge;25 weeks) reported a mean loading dose of 9.6 &plusmn; 1.5 mg/kg and a mean continuous infusion rate of 37.56 &plusmn; 13.52 mcg/kg/minute;",
"     <b>",
"      Note:",
"     </b>",
"     Procainamide serum concentrations were supratherapeutic in five neonates studied; four of the five were &lt;36 weeks GA and all five had Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt; 30 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     ; these results indicate that doses may need to be decreased in preterm neonates and in those with renal impairment (Moffett, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"      see \"Procainamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be titrated to patient's response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 20-30 mg/kg/day divided every 4-6 hours; maximum: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: 3-6 mg/kg/dose over 5 minutes, not to exceed 100 mg/dose; may repeat every 5-10 minutes to maximum total loading dose of 15 mg/kg; do not exceed 500 mg in 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: Continuous I.V. infusion: 20-80 mcg/kg/minute; maximum dose: 2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stable wide-complex tachycardia of unknown origin (atrial or ventricular) or SVT (PALS, 2010):",
"     <b>",
"      Note:",
"     </b>",
"     Avoid or use extreme caution when administering procainamide with other drugs that prolong QT interval (eg, amiodarone); consider consulting with expert",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.O.: Loading dose: 15 mg/kg infused over 30-60 minutes; monitor ECG and blood pressure; stop the infusion if hypotension occurs or QRS complex widens by &gt;50% of baseline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 50 mg/kg/day divided every 3-6 hours",
"     <b>",
"      or",
"     </b>",
"     0.5-1 g every 4-8 hours (Koch-Weser, 1971)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: 15-18 mg/kg administered as slow infusion over 25-30 minutes",
"     <b>",
"      or",
"     </b>",
"     100 mg/dose at a rate not to exceed 50 mg/minute repeated every 5 minutes as needed to a total dose of 1 g. Reduce loading dose to 12 mg/kg in severe renal or cardiac impairment. Follow with maintenance dose as continuous I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodynamically stable monomorphic VT or pre-excited atrial fibrillation (ACLS, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: Infuse 20 mg/minute (up to 50 mg/minute for more urgent situations) or 100 mg every 5 minutes until arrhythmia is controlled, hypotension occurs, QRS complex widens by 50% of its original width, or total of 17 mg/kg is given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 1-4 mg/minute by continuous I.V. infusion. Maintenance infusions should be reduced by one-third in patients with moderate renal or cardiac impairment and by two-thirds in patients with severe renal or cardiac impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: Reduce dose to 12 mg/kg in severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance infusion: Reduce dose by one-third in patients with mild renal impairment. Reduce dose by two-thirds in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Procainamide: Moderately hemodialyzable (20% to 50%): Monitor procainamide/N-acetylprocainamide (NAPA) levels; supplementation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     NAPA: Not dialyzable (0% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Procainamide/NAPA: Not peritoneal dialyzable (0% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Procainamide/NAPA: Replace by blood level during continuous arteriovenous or venovenous hemofiltration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment",
"     </b>",
"     : Reduce dose by 50%.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 100 mg/mL (10 mL); 500 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Administer I.V. loading dose over 30-60 minutes; decrease infusion rate if QT interval becomes prolonged or patient develops heart block; discontinue the infusion if patient develops hypotension or QRS interval widens to &gt;50% of baseline (PALS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: I.V.: Usual rate of infusion: 20-50 mg/minute; do not administer faster than 50 mg/minute (ACLS, 2010); severe hypotension can occur with rapid I.V. administration; administer I.V. loading doses and intermittent infusions over 25-30 minutes; use concentration of 20-30 mg/mL for loading dose and 2-4 mg/mL for maintenance infusions; rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F213589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"     <b>",
"      Note:",
"     </b>",
"     Some information indicates that procainamide may be subject to greater decomposition in D",
"     <sub>",
"      5",
"     </sub>",
"     W unless the admixture is refrigerated or the pH is adjusted. Procainamide is believed to form an association complex with dextrose - the bioavailability of procainamide in this complex is not known and the complex formation is reversible (Raymond, 1988).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, bivalirudin, cisatracurium, dexmedetomidine, famotidine, fenoldopam, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, metoprolol, nitroprusside, pancuronium, pantoprazole, potassium chloride, ranitidine, remifentanil, vasopressin, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Milrinone.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem, inamrinone, nesiritide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); use only clear or slightly yellow solutions; stability of parenteral admixture with D",
"     <sub>",
"      5",
"     </sub>",
"     W at room temperature (25&deg;C) is 24 hours and 7 days at refrigerated temperature (2&deg;C to 8&deg;C)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ventricular arrhythmias (eg, sustained ventricular tachycardia) (FDA approved in adults); has also been used for symptomatic premature ventricular contractions, atrial fibrillation.",
"     <b>",
"      Note:",
"     </b>",
"     Due to proarrhythmic effects, use should be reserved for life-threatening arrhythmias.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Procainamide is recommended in the PALS guidelines for tachycardia with pulses and poor perfusion [ie, SVT (unresponsive to vagal maneuvers and adenosine) and wide-complex (&gt;0.09 sec) VT (unresponsive to synchronized cardioversion or adenosine)]. It is recommended in the ACLS guidelines as one of several drugs that can be considered for treatment of the following arrhythmias in patients with preserved ventricular function: Stable monomorphic VT; pre-excited atrial fibrillation; stable wide complex regular tachycardia (likely VT).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Procanbid may be confused with probenecid, Procan SR&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pronestyl may be confused with Ponstel&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Procainamide hydrochloride is available in 10 mL vials of 100 mg/mL and in 2 mL vials with 500 mg/mL. Note that",
"       <b>",
"        BOTH",
"       </b>",
"       vials contain 1 gram of drug; confusing the strengths can lead to massive overdoses or underdoses.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PCA is an error-prone abbreviation (mistaken as patient controlled analgesia)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F213588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, taste disorder, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alkaline phosphatase increased, angioedema, anorexia, aplastic anemia, arrhythmia exacerbated, arthralgia, asystole, bone marrow suppression, cerebellar ataxia, confusion, demyelinating polyradiculoneuropathy, disorientation, dizziness, drug fever, fever, first degree heart block, flushing, granulomatous hepatitis, hallucinations, hemolytic anemia, hepatic failure, hyperbilirubinemia, hypoplastic anemia, intrahepatic cholestasis, leukopenia, lightheadedness, maculopapular rash, mania, mental depression, myasthenia gravis worsened, myocardial contractility depressed, myocarditis, myopathy, neuromuscular blockade, neutropenia, pancreatitis, pancytopenia, paradoxical increase in ventricular rate in atrial fibrillation/flutter, peripheral/polyneuropathy, pleural effusion, positive Coombs' test, proarrhythmia, pseudo-obstruction, psychosis, pulmonary embolism,  QT",
"     <sub>",
"      c",
"     </sub>",
"     -interval prolongation, pruritus, rash, respiratory failure due to myopathy, second-degree heart block, tachycardia, thrombocytopenia, torsade de pointes, transaminases increased, urticaria, vasculitis, ventricular fibrillation, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to procainamide, procaine, related drugs, or any component; complete heart block; second degree heart block or various types of hemiblock without a functional artificial pacemaker; \"torsade de pointes\" (twisting of the points); SLE",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with marked A-V conduction disturbances, bundle-branch block or severe cardiac glycoside intoxication, ventricular arrhythmias in patients with organic heart disease or coronary occlusion, CHF, supraventricular tachyarrhythmias unless digitalis glycoside levels are adequate to prevent marked increases in ventricular rates. Use with caution with concurrent use of other antiarrhythmics; may exacerbate or increase the risk of conduction disturbances. Drug may accumulate in patients with renal or hepatic dysfunction; use with caution; dosage adjustment required. Avoid use in myasthenia gravis; may worsen condition. An interruption of procainamide infusion may be required if a significant widening of the QRS complex or marked QT prolongation occurs (this may indicate overdosage). Use with extreme caution in patients with pre-existing QT prolongation; may increase risk for development of torsades de pointes.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potentially fatal blood dyscrasias have occurred with therapeutic doses",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; close monitoring is recommended during the first 3 months of therapy and periodically thereafter. Long-term administration leads to the development of a positive antinuclear antibody (ANA) test in 50% of patients which may lead to a lupus erythematosus-like syndrome (in 20% to 30% of patients)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; assess relative benefits and risks if ANA titer becomes positive and consider alternative agent; discontinue procainamide if SLE symptoms develop and change to alternative agent; injection contains sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the excretion of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of Procainamide. Management: Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine.  The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: May enhance the QTc-prolonging effect of Procainamide. Management: Consider alternatives to procainamide in patients with acute lurasidone overdose.  If procainamide treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Procainamide may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10950407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Procainamide crosses the placenta; procainamide and its active metabolite (N-acetyl procainamide) can be detected in the cord blood and neonatal serum.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, blood pressure; CBC with differential and platelet counts at weekly intervals for the first 3 months of treatment, periodically thereafter, or if signs of infection, bruising or bleeding occur; antinuclear antibody test (ANA); renal function; serum drug concentrations (procainamide and NAPA) especially in patients with hepatic impairment, renal failure, or those receiving higher maintenance doses (eg, adults: &gt;3 mg/minute) for &gt;24 hours",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procainamide: 4-10 mcg/mL (SI: 15-37 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sum of procainamide and N-acetyl procainamide: 10-30 mcg/mL (SI: &lt;110 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optimal ranges must be ascertained for individual patients, with ECG monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic (procainamide): &gt;10-12 mcg/mL (SI: &gt;37-44 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class IA antiarrhythmic with anticholinergic and local anesthetic effects; decreases myocardial excitability and conduction velocity and depresses myocardial contractility, by increasing the electrical stimulation threshold of ventricle, His-Purkinje system and through direct cardiac effects",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1055120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: I.M. 10-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (decreased with CHF or shock):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By acetylation in the liver to produce N-acetyl procainamide (NAPA) (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procainamide (dependent upon hepatic acetylator phenotype, cardiac function, and renal function):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults with normal renal function: 2.5-4.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NAPA (dependent upon renal function):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults with normal renal function: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: 15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urinary excretion (25% as NAPA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable by hemodialysis (20% to 50%), but not dialyzable by peritoneal dialysis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chang PM, Silka MJ, Moromisato DY, et al, \"Amiodarone Versus Procainamide for the Acute Treatment of Recurrent Supraventricular Tachycardia in Pediatric Patients,\"",
"      <i>",
"       Circ Arrhythm Electrophysiol",
"      </i>",
"      , 2010, 3(2):134-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/18/38182/abstract-text/20194798/pubmed\" id=\"20194798\" target=\"_blank\">",
"        20194798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, \"Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/18/38182/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, \"Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, Nov, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/18/38182/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koch-Weser J and Klein SW, &ldquo;Procainamide Dosage Schedules, Plasma Concentrations, and Clinical Effects,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1971, 215(9):1454-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/18/38182/abstract-text/5107621/pubmed\" id=\"5107621\" target=\"_blank\">",
"        5107621",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moffett BS, Cannon BC, Friedman RA, et al, \"Therapeutic Levels of Intravenous Procainamide in Neonates: A Retrospective Assessment,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(12):1687-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/18/38182/abstract-text/17125432/pubmed\" id=\"17125432\" target=\"_blank\">",
"        17125432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/18/38182/abstract-text/20956224/pubmed\" id=\"20956224\" target=\"_blank\">",
"        20956224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh S, Gelband H, Mehta AV, et al, &ldquo;Procainamide Elimination Kinetics in Pediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1982, 32(5):607-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/18/38182/abstract-text/7128001 /pubmed\" id=\"7128001 \" target=\"_blank\">",
"        7128001",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12732 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38182=[""].join("\n");
var outline_f37_18_38182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709347\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213545\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055112\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675549\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055105\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213516\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213501\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055117\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213589\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055108\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055116\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213591\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213588\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055122\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055104\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055103\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213576\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213510\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213512\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10950407\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055111\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055115\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055102\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055120\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055121\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=related_link\">",
"      Procainamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/45/4820?source=related_link\">",
"      Procainamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_18_38183="Extubation management";
var content_f37_18_38183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extubation management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38183/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38183/contributors\">",
"     Kristy A Bauman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38183/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38183/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38183/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38183/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38183/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/18/38183/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extubation refers to removal of the endotracheal tube (ETT). It is the final step in liberating a patient from mechanical ventilation. Issues that need to be considered prior to extubation, the extubation procedure itself, and management after extubation are described here. Outcomes following extubation are also discussed. Predictors of weaning success and methods of weaning from mechanical ventilation are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21112?source=see_link\">",
"     \"Weaning from mechanical ventilation: Readiness testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIOR TO EXTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the end of the weaning process, it may be apparent that a patient no longer requires mechanical ventilation to maintain sufficient ventilation and oxygenation. However, extubation should not be ordered until it has been determined that the patient is able to protect the airway and the airway is patent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Airway protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway protection is the ability to guard against aspiration during spontaneous breathing. It requires sufficient cough strength and an adequate level of consciousness, each of which should be assessed prior to extubation. The amount of secretions should also be considered prior to extubation because airway protection is significantly more difficult when secretions are increased.",
"   </p>",
"   <p>",
"    The importance of cough strength and the amount of secretions was illustrated by two observational studies that showed that successful extubation directly correlated with strength of the spontaneous cough and inversely correlated with the frequency of suctioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These studies were limited by their use of semiobjective measures of cough strength and secretion amount. Several subsequent studies addressed this limitation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 130 patients who had passed a spontaneous breathing trial demonstrated that extubation failure was more likely among patients who were unable to cough on command or who had a peak expiratory flow rate during a cough of &lt;35",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      (24 versus 3.5 percent, relative risk 6.9, 95% CI 2.0-24) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another observational study enrolled 88 patients who had passed a spontaneous breathing trial and were being considered for extubation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/4\">",
"       4",
"      </a>",
"      ]. Extubation failure occurred in 14 patients (16 percent). Patients were more likely to fail extubation if their peak expiratory flow during a cough was &le;60",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      (relative risk 4.8, 95% CI 1.4-16.2) or their secretions were &gt;2.5",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      (relative risk 3.0, 95% CI 1.0-8.8). The study was limited by its small sample size, leading to imprecise estimates of the magnitude of effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several methods have been described that can be used in intubated patients to help determine whether the cough strength is sufficient to clear secretions following extubation. Two of the methods require cooperative patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A spirometer is inserted into the ventilator circuit and the patient is then instructed to cough. The peak expiratory flow (PEF) during the cough is measured. Patients with a PEF &le;60",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      are five times more likely to require reintubation than patients with a PEF &gt;60",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The endotracheal tube (ETT) is detached from the ventilator circuit and a card (eg, an index card) is held approximately 1 to 2 cm from the proximal end of the ETT. The patient is then instructed to cough. A patient who is unable to moisten the card with 3 to 4 coughs is three times more likely to fail extubation than a patient who can moisten the card [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of level of consciousness has also been demonstrated in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 100 neurosurgical patients, patients with a Glasgow Coma Score (GCS) &ge;8 were significantly more likely to undergo successful extubation than patients with a GCS &lt;8 (75 versus 37 percent) (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the observational study of 88 patients cited above, the inability to complete four commands (open eyes, follow object with eyes, grasp hand, stick out tongue) was associated with an increased risk of extubation failure (relative risk 4.3, 95% CI 1.8-10.4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When all three risk factors were present - reduced cough peak expiratory flow rate (&le;60",
"    <span class=\"nowrap\">",
"     L/min),",
"    </span>",
"    increased sputum volume (&gt;2.5",
"    <span class=\"nowrap\">",
"     mL/hr),",
"    </span>",
"    and impaired neurologic function (inability to follow the four commands described above) - the incidence of extubation failure was 100 percent, compared to 3 percent when none of the risk factors were present (relative risk 23, 95% CI 3.2-167) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Universally accepted threshold levels of cough strength, level of consciousness, and suctioning frequency that prohibit extubation have not been established. For many patients, it seems reasonable to delay extubation if the cough strength is weak, the GCS is &lt;8, or suctioning is required more frequently than every two to three hours. However, the final decision to delay or proceed with extubation should be made on a case-by-case basis since delayed extubation is associated with adverse outcomes, such as ventilator-associated pneumonia and increased length of stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Airway patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications related to the ETT can affect airway patency and may not be detectable until after extubation. Testing for a cuff leak prior to extubation is the most common method used to determine whether airway patency may be decreased. Risk factors for postextubation laryngeal edema include prolonged intubation (variably defined as &ge;36 hours to &ge;6 days), age greater than 80 years, a large endotracheal tube (&gt;8 mm in men, &gt;7 mm in women), a ratio of ETT to laryngeal diameter greater than 45 percent, a small ratio of patient height to ETT diameter, an elevated APACHE II score, a GCS score &lt; 8, traumatic intubation, female gender, a history of asthma, excessive tube mobility due to insufficient fixation, insufficient or lack of sedation, aspiration, and the presence of an orogastric or nasogastric tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link&amp;anchor=H7#H7\">",
"     \"Endotracheal tube management and complications\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cuff leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"cuff leak\" refers to normal airflow around the ETT after the cuff of the ETT is deflated. Its absence suggests there is reduced space between the ETT and the larynx. This may be due to laryngeal edema, another laryngeal injury, secretions, or a large ETT within a relatively small larynx. Patients without a cuff leak are at increased risk for post-extubation stridor.",
"   </p>",
"   <p>",
"    The cuff leak can be detected qualitatively or quantitatively:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Qualitative assessment is performed by deflating the cuff and then listening for air movement around the ETT using a stethoscope placed over the upper trachea.",
"     </li>",
"     <li>",
"      Quantitative assessment is performed by deflating the ETT cuff and measuring the difference between the inspired and expired tidal volumes of ventilator-delivered breaths during volume-cycled mechanical ventilation. The lowest three expired tidal volumes obtained over six breaths are averaged and then subtracted from the inspired tidal volume to give the cuff leak volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/15\">",
"       15",
"      </a>",
"      ]. Cuff leak volumes less than 110 mL or less than 12 to 24 percent of the delivered tidal volume have been suggested as thresholds for determining whether airway patency may be diminished [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/9,11,15-18\">",
"       9,11,15-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simultaneous assessment of both cough and cuff leak may improve prediction of post-extubation stridor. After the cuff is deflated, the ETT is occluded and the patient is instructed to cough. The absence of both an audible cough and a cuff leak indicates the patient is 10 times more likely to develop post-extubation stridor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absence of a cuff leak alone is an imperfect predictor of post-extubation stridor. The cuff leak predicts post-extubation stridor with a sensitivity of 15 to 85 percent and a specificity of 72 to 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/9,10,15-17\">",
"     9,10,15-17",
"    </a>",
"    ]. These wide ranges likely reflect variability in the patient populations, how the cuff leak was measured, and what was considered an acceptable cuff leak. A pooled analysis found a sensitivity and specificity of 56 and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients are safely extubated despite an absent cuff leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Generally speaking, it is reasonable to proceed with extubation if a cuff leak exists, but to delay extubation if a cuff leak is reduced and there are risk factors for laryngeal edema (eg, prolonged intubation). Extubation should be considered on an individual basis in patients who have an absent cuff leak, but no risk factors for laryngeal edema and otherwise appear ready for extubation. Risk factors for laryngeal injury are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link&amp;anchor=H8#H8\">",
"     \"Endotracheal tube management and complications\", section on 'Laryngeal injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laryngeal ultrasonography is a simple, rapid, and noninvasive way to evaluate the width of the laryngeal air column during cuff deflation, thereby assessing the likelihood of postextubation stridor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/22\">",
"     22",
"    </a>",
"    ]. Although promising, this modality is not recommended for routine use until controlled clinical trials are performed.",
"   </p>",
"   <p>",
"    For patients whose initial trial of extubation failed due to stridor and who are now being considered for extubation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a cuff leak is detected, bedside extubation is generally safe.",
"     </li>",
"     <li>",
"      If a cuff leak is absent despite a course of glucocorticoid therapy, extubation over an airway exchange catheter (ie, a Cook catheter) may facilitate successful reintubation without delay, if necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/23\">",
"       23",
"      </a>",
"      ]. Extubation of such patients in a controlled environment, such as the operating room, should also be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data about the efficacy of glucocorticoids at preventing post-extubation stridor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/11,12,24-27\">",
"     11,12,24-27",
"    </a>",
"    ]. The inconsistency may be related to differences in the risk of post-extubation stridor among the patients studied",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the duration of glucocorticoid therapy prior to extubation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trials that enrolled patients at increased risk for post-extubation stridor and administered multiple doses of glucocorticoids prior to extubation have found statistically significant reductions in the rates of post-extubation stridor and reintubation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Meta-analyses further support the notion that glucocorticoids given prior to extubation reduce the rate of post-extubation stridor and reintubation when given in multiple doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/26-28\">",
"       26-28",
"      </a>",
"      ] or when given to properly selected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, trials that enrolled unselected patients and administered a single dose of glucocorticoids shortly prior to extubation did not find statistically significant improvement in the rates of post-extubation stridor and reintubation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We believe that the risk for post-extubation stridor is more important than the number of doses administered when deciding whether giving glucocorticoids prior to extubation may be beneficial. This is supported by a trial that randomly assigned 71 patients with a cuff leak of less than 24 percent of the tidal volume administered by the ventilator to receive either a saline placebo or a single dose of 40 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    four hours prior to extubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/30\">",
"     30",
"    </a>",
"    ]. The group that received the methylprednisolone had significantly decreased rates of post-extubation stridor (16 versus 39 percent) and reintubation (8 versus 30 percent) than the group that received the placebo.",
"   </p>",
"   <p>",
"    We suggest that patients whose extubation is delayed due to a reduced cuff leak receive a short course of glucocorticoid therapy before extubation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     Methylprednisolone",
"    </a>",
"    (20 mg) administered every four hours for a total of four doses prior to extubation is an acceptable regimen. Alternatively, a single dose of 40 mg of methylprednisolone administered four hours prior to extubation may be used.",
"   </p>",
"   <p>",
"    We limit glucocorticoid therapy to those patients who have a reduced cuff leak, since the overall incidence of postextubation laryngeal edema requiring reintubation is low (less than 5 percent). We believe this approach focuses therapy on those who are most likely to benefit and avoids unnecessarily prolonging mechanical ventilation for glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXTUBATION PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is placed into an upright position and both the oral cavity and the endotracheal tube (ETT) are suctioned. Instructions are given for the patient to take a deep breath and then exhale. During exhalation, the cuff is deflated and the ETT is removed in a single, smooth motion. Orogastric tubes are typically removed simultaneously.",
"   </p>",
"   <p>",
"    Following extubation, the oral cavity is again suctioned and supplemental oxygen is administered by facemask. The oxyhemoglobin saturation, heart rate, respiratory rate, and blood pressure are monitored throughout the extubation process. Patients with increased secretions may require more frequent or nasotracheal suctioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POST-EXTUBATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patients should be closely monitored following extubation. In many cases, early aggressive management can prevent reintubation. This may include suctioning, bronchodilator therapy, diuresis, or noninvasive positive pressure ventilation (NPPV).",
"   </p>",
"   <p>",
"    The evidence suggests that NPPV may prevent post-extubation respiratory failure if it is applied soon after extubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 162 patients considered at risk of developing post-extubation respiratory failure to receive conventional medical therapy with or without NPPV for 24 hours immediately following extubation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients were considered at risk of post-extubation respiratory failure if they were 65 years or older, had an Acute Physiology and Chronic Health Evaluation (APACHE) II score &gt;12 on the day of extubation, or had required intubation due to cardiac failure. NPPV was associated with lower intensive care unit mortality (3 versus 14 percent), but not a lower reintubation rate, hospital mortality, or 90-day mortality. A pre-defined subgroup analysis found that the benefit of NPPV was limited to patients who had hypercapnia (arterial carbon dioxide tension [PaCO2] &gt;45 mmHg) during a pre-extubation spontaneous breathing trial, 98 percent of whom had chronic lung disease.",
"     </li>",
"     <li>",
"      Another trial randomly assigned 208 patients with chronic hypercapnic respiratory failure to undergo conventional extubation, extubation followed by supplemental oxygen, or extubation followed by immediate NPPV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/35\">",
"       35",
"      </a>",
"      ]. The group that received immediate NPPV was less likely to develop post-extubation acute respiratory failure, defined as tachypnea (&gt;30",
"      <span class=\"nowrap\">",
"       breaths/min),",
"      </span>",
"      bradypnea (&lt;12",
"      <span class=\"nowrap\">",
"       breaths/min),",
"      </span>",
"      hypoxemia (SpO2 &lt;90 percent, PaO2 &lt;64 mmHg, or",
"      <span class=\"nowrap\">",
"       PaO2/FiO2",
"      </span>",
"      &le;130 mmHg despite supplemental oxygen at a flow rate &gt;6",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      or an FiO2 &ge;50 percent), respiratory acidosis (PaCO2 increase of &ge;10 percent and a pH &le;7.35), or clinical signs of acute respiratory failure (eg, diaphoresis, use of accessory respiratory muscles). However, there was no difference in the mortality or reintubation rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, NPPV appears ineffective and potentially harmful if it is not initiated until after the onset of post-extubation respiratory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. This was illustrated by a trial of 221 patients who developed respiratory failure after extubation and then were randomly assigned to receive conventional medical therapy with or without NPPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/36\">",
"     36",
"    </a>",
"    ]. Respiratory failure was defined as two or more of the following: respiratory acidosis (pH &lt;7.35 with a PaCO2 &gt;45 mmHg), clinical signs of respiratory fatigue (ie, use of accessory muscles, intercostal retractions, paradoxical motion of the abdomen), a respiratory rate &gt;25",
"    <span class=\"nowrap\">",
"     breaths/min",
"    </span>",
"    for two consecutive hours, or hypoxemia (arterial oxygen tension &lt;80 mmHg or arterial oxyhemoglobin saturation &lt;90 percent despite a fraction of inspired oxygen &gt;50 percent). All-cause mortality increased in the NPPV group (25 versus 14 percent), resulting in early termination of the trial. The increased mortality may have been related to delayed reintubation.",
"   </p>",
"   <p>",
"    In light of these data, we suggest that patients who have hypercapnia during their pre-extubation spontaneous breathing trial receive NPPV immediately following extubation.",
"   </p>",
"   <p>",
"    Patients who are significantly hypoxemic following extubation may be treated with either a high flow face mask or high flow nasal prongs. High flow nasal prongs are better tolerated and provide some PEEP, particularly if the patient&rsquo;s mouth is closed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/38\">",
"     38",
"    </a>",
"    ]. A trial of NPPV is reasonable in patients if impending acute hypercapnic respiratory failure is suspected. However, patients should be promptly intubated if they either (a) fail the trial of NPPV or (b) develop definitive acute respiratory failure before the trial of NPPV can be initiated. We define acute respiratory failure as defined by the trial of 208 patients described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes following extubation are related to whether the extubation was planned or unplanned. Generally speaking, outcomes are better following planned extubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Unplanned extubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who undergo unplanned extubation (ie, self-extubation) should be promptly reintubated because delayed reintubation is associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/39\">",
"     39",
"    </a>",
"    ]. This is probably because reintubation after unplanned extubation is often technically difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Careful observation is appropriate for only a minority of patients who are clinically stable, have low ventilatory and oxygenation requirements, have a patent airway, and can protect their airway. Clearance of airway secretions (aggressive suctioning) is critical to avoid reintubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/43\">",
"     43",
"    </a>",
"    ]. Unplanned extubation is associated with a longer duration of mechanical ventilation, ICU stay, and hospitalization compared to matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unplanned extubation occurs in 3 to 12 percent of intubated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/40,44-52\">",
"     40,44-52",
"    </a>",
"    ]. It is more common in patients who are orally intubated than those who are nasally intubated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/40,48-51\">",
"     40,48-51",
"    </a>",
"    ]. It is also more frequent in patients whose endotracheal tube (ETT) is not well secured or who are agitated, have low levels of sedation, or are physically restrained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/49,50,53,54\">",
"     49,50,53,54",
"    </a>",
"    ]. Most unplanned extubations occur within one day of planned extubation and are deliberate rather than accidental [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 percent of patients who have undergone unplanned extubation require reintubation, often within 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. Reintubation is more common following accidental unplanned extubation and among patients who require full ventilatory support, have higher sedation scores, and have a significant oxygen requirement (ie, fraction of inspired oxygen &gt;50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/40,41,48,50,53\">",
"     40,41,48,50,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Extubation failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 12 to 14 percent of patients who undergo planned extubation require reintubation within 48 to 72 hours, most within the first 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/39,52,56,57\">",
"     39,52,56,57",
"    </a>",
"    ]. Risk factors for reintubation include a weak cough and frequent suctioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/52\">",
"     52",
"    </a>",
"    ]. Additional features that may predict reintubation include a rapid shallow breathing index &gt;58",
"    <span class=\"nowrap\">",
"     breaths/min",
"    </span>",
"    per L, a positive fluid balance during the 24 hours preceding extubation, and pneumonia as the reason for the initial intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients who are &ge;65 years old with severe chronic cardiac or respiratory disease appear to be at particularly high risk for extubation failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of reintubation depends on the patient population. In medical intensive care unit (ICU) patients, reintubation is associated with increased hospital mortality, a longer ICU stay, longer hospitalization, and nosocomial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Mortality is highest among those who fail extubation late (&gt;12 hours after extubation) or who require reintubation for reasons unrelated to the airway (ie, respiratory failure, heart failure, or encephalopathy instead of stridor) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/39\">",
"     39",
"    </a>",
"    ]. In contrast, reintubation is not associated with increased mortality in cardiac surgery patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38183/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extubation refers to removal of the endotracheal tube (ETT). It is the final step in liberating a patient from mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it is determined that a patient no longer requires mechanical ventilation to maintain sufficient ventilation and oxygenation, the patient's ability to protect the airway and airway patency should be evaluated in preparation for possible extubation. The former involves assessment of cough, level of consciousness, and amount of secretions, while the latter involves looking for a cuff leak. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Airway protection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Cuff leak'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients whose cough strength is weak, whose Glasgow Coma Score is &lt;8, or who require suctioning more frequently than every two to three hours, we suggest delaying extubation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The cause of the impairment should then be sought and corrected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Airway protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients who have a reduced cuff leak plus one or more risk factors for laryngeal edema (prolonged duration of intubation, traumatic intubation, large endotracheal tube, aspiration, presence of an orogastric or nasogastric tube), we suggest delaying extubation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest a short course of glucocorticoid therapy for such patients, rather than no glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Airway patency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extubation should be decided on a case-by-case basis for patients who have a reduced cuff leak, but no risk factors for laryngeal edema. Similarly, extubation should be decided on a case-by-case basis for patients who have risk factors for laryngeal edema, but no reduced cuff leak. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Airway patency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be closely monitored following extubation. In many cases, aggressive management early can prevent reintubation. This may include suctioning, bronchodilator therapy, diuresis, or noninvasive positive pressure ventilation (NPPV). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Post-extubation management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have hypercapnia during their pre-extubation spontaneous breathing trial, we suggest NPPV immediately following extubation. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Post-extubation management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all other patients who are extubated, we suggest that NPPV be initiated as soon as it is suspected that a patient may be failing extubation, rather than waiting until there is definitive evidence of respiratory failure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Post-extubation management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who fail a trial of NPPV or develop definitive respiratory failure before NPPV can be initiated, we recommend prompt reintubation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Post-extubation management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is estimated that 12 to 14 percent of patients who undergo planned extubation require reintubation. In contrast, up to 50 percent of patients who undergo unplanned extubation require reintubation. Unplanned extubation is associated with increased mortality. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/1\">",
"      Coplin WM, Pierson DJ, Cooley KD, et al. Implications of extubation delay in brain-injured patients meeting standard weaning criteria. Am J Respir Crit Care Med 2000; 161:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/2\">",
"      Khamiees M, Raju P, DeGirolamo A, et al. Predictors of extubation outcome in patients who have successfully completed a spontaneous breathing trial. Chest 2001; 120:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/3\">",
"      Beuret P, Roux C, Auclair A, et al. Interest of an objective evaluation of cough during weaning from mechanical ventilation. Intensive Care Med 2009; 35:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/4\">",
"      Salam A, Tilluckdharry L, Amoateng-Adjepong Y, Manthous CA. Neurologic status, cough, secretions and extubation outcomes. Intensive Care Med 2004; 30:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/5\">",
"      Epstein SK. Putting it all together to predict extubation outcome. Intensive Care Med 2004; 30:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/6\">",
"      Smina M, Salam A, Khamiees M, et al. Cough peak flows and extubation outcomes. Chest 2003; 124:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/7\">",
"      Namen AM, Ely EW, Tatter SB, et al. Predictors of successful extubation in neurosurgical patients. Am J Respir Crit Care Med 2001; 163:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/8\">",
"      Maury E, Guglielminotti J, Alzieu M, et al. How to identify patients with no risk for postextubation stridor? J Crit Care 2004; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/9\">",
"      Kriner EJ, Shafazand S, Colice GL. The endotracheal tube cuff-leak test as a predictor for postextubation stridor. Respir Care 2005; 50:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/10\">",
"      Sukhupanyarak S. Risk factors evaluation and the cuff leak test as predictors for postextubation stridor. J Med Assoc Thai 2008; 91:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/11\">",
"      Cheng KC, Hou CC, Huang HC, et al. Intravenous injection of methylprednisolone reduces the incidence of postextubation stridor in intensive care unit patients. Crit Care Med 2006; 34:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/12\">",
"      Fran&ccedil;ois B, Bellissant E, Gissot V, et al. 12-h pretreatment with methylprednisolone versus placebo for prevention of postextubation laryngeal oedema: a randomised double-blind trial. Lancet 2007; 369:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/13\">",
"      Santos PM, Afrassiabi A, Weymuller EA Jr. Risk factors associated with prolonged intubation and laryngeal injury. Otolaryngol Head Neck Surg 1994; 111:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/14\">",
"      Friedman M, Baim H, Shelton V, et al. Laryngeal injuries secondary to nasogastric tubes. Ann Otol Rhinol Laryngol 1981; 90:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/15\">",
"      Miller RL, Cole RP. Association between reduced cuff leak volume and postextubation stridor. Chest 1996; 110:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/16\">",
"      Jaber S, Chanques G, Matecki S, et al. Post-extubation stridor in intensive care unit patients. Risk factors evaluation and importance of the cuff-leak test. Intensive Care Med 2003; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/17\">",
"      De Bast Y, De Backer D, Moraine JJ, et al. The cuff leak test to predict failure of tracheal extubation for laryngeal edema. Intensive Care Med 2002; 28:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/18\">",
"      Lee CH, Peng MJ, Wu CL. Dexamethasone to prevent postextubation airway obstruction in adults: a prospective, randomized, double-blind, placebo-controlled study. Crit Care 2007; 11:R72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/19\">",
"      Ochoa ME, Mar&iacute;n Mdel C, Frutos-Vivar F, et al. Cuff-leak test for the diagnosis of upper airway obstruction in adults: a systematic review and meta-analysis. Intensive Care Med 2009; 35:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/20\">",
"      Fisher MM, Raper RF. The 'cuff-leak' test for extubation. Anaesthesia 1992; 47:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/21\">",
"      Engoren M. Evaluation of the cuff-leak test in a cardiac surgery population. Chest 1999; 116:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/22\">",
"      Ding LW, Wang HC, Wu HD, et al. Laryngeal ultrasound: a useful method in predicting post-extubation stridor. A pilot study. Eur Respir J 2006; 27:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/23\">",
"      Mort TC. Continuous airway access for the difficult extubation: the efficacy of the airway exchange catheter. Anesth Analg 2007; 105:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/24\">",
"      Darmon JY, Rauss A, Dreyfuss D, et al. Evaluation of risk factors for laryngeal edema after tracheal extubation in adults and its prevention by dexamethasone. A placebo-controlled, double-blind, multicenter study. Anesthesiology 1992; 77:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/25\">",
"      Ho LI, Harn HJ, Lien TC, et al. Postextubation laryngeal edema in adults. Risk factor evaluation and prevention by hydrocortisone. Intensive Care Med 1996; 22:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/26\">",
"      Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. Cochrane Database Syst Rev 2009; :CD001000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/27\">",
"      Fan T, Wang G, Mao B, et al. Prophylactic administration of parenteral steroids for preventing airway complications after extubation in adults: meta-analysis of randomised placebo controlled trials. BMJ 2008; 337:a1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/28\">",
"      McCaffrey J, Farrell C, Whiting P, et al. Corticosteroids to prevent extubation failure: a systematic review and meta-analysis. Intensive Care Med 2009; 35:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/29\">",
"      Jaber S, Jung B, Chanques G, et al. Effects of steroids on reintubation and post-extubation stridor in adults: meta-analysis of randomised controlled trials. Crit Care 2009; 13:R49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/30\">",
"      Cheng KC, Chen CM, Tan CK, et al. Methylprednisolone reduces the rates of postextubation stridor and reintubation associated with attenuated cytokine responses in critically ill patients. Minerva Anestesiol 2011; 77:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/31\">",
"      Nava S, Gregoretti C, Fanfulla F, et al. Noninvasive ventilation to prevent respiratory failure after extubation in high-risk patients. Crit Care Med 2005; 33:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/32\">",
"      Ferrer M, Valencia M, Nicolas JM, et al. Early noninvasive ventilation averts extubation failure in patients at risk: a randomized trial. Am J Respir Crit Care Med 2006; 173:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/33\">",
"      El-Solh AA, Aquilina A, Pineda L, et al. Noninvasive ventilation for prevention of post-extubation respiratory failure in obese patients. Eur Respir J 2006; 28:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/34\">",
"      Ferrer M, Sellar&eacute;s J, Valencia M, et al. Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. Lancet 2009; 374:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/35\">",
"      Girault C, Bubenheim M, Abroug F, et al. Noninvasive ventilation and weaning in patients with chronic hypercapnic respiratory failure: a randomized multicenter trial. Am J Respir Crit Care Med 2011; 184:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/36\">",
"      Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med 2004; 350:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/37\">",
"      Keenan SP, Powers C, McCormack DG, Block G. Noninvasive positive-pressure ventilation for postextubation respiratory distress: a randomized controlled trial. JAMA 2002; 287:3238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/38\">",
"      Tiruvoipati R, Lewis D, Haji K, Botha J. High-flow nasal oxygen vs high-flow face mask: a randomized crossover trial in extubated patients. J Crit Care 2010; 25:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/39\">",
"      Epstein SK, Ciubotaru RL. Independent effects of etiology of failure and time to reintubation on outcome for patients failing extubation. Am J Respir Crit Care Med 1998; 158:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/40\">",
"      Razek T, Gracias V, Sullivan D, et al. Assessing the need for reintubation: a prospective evaluation of unplanned endotracheal extubation. J Trauma 2000; 48:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/41\">",
"      Krinsley JS, Barone JE. The drive to survive: unplanned extubation in the ICU. Chest 2005; 128:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/42\">",
"      Epstein SK, Nevins ML, Chung J. Effect of unplanned extubation on outcome of mechanical ventilation. Am J Respir Crit Care Med 2000; 161:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/43\">",
"      de Larminat V, Montravers P, Dureuil B, Desmonts JM. Alteration in swallowing reflex after extubation in intensive care unit patients. Crit Care Med 1995; 23:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/44\">",
"      Coppolo DP, May JJ. Self-extubations. A 12-month experience. Chest 1990; 98:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/45\">",
"      Vassal T, Anh NG, Gabillet JM, et al. Prospective evaluation of self-extubations in a medical intensive care unit. Intensive Care Med 1993; 19:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/46\">",
"      Listello D, Sessler CN. Unplanned extubation. Clinical predictors for reintubation. Chest 1994; 105:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/47\">",
"      Tindol GA Jr, DiBenedetto RJ, Kosciuk L. Unplanned extubations. Chest 1994; 105:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/48\">",
"      Betbes&eacute; AJ, P&eacute;rez M, Bak E, et al. A prospective study of unplanned endotracheal extubation in intensive care unit patients. Crit Care Med 1998; 26:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/49\">",
"      Boulain T. Unplanned extubations in the adult intensive care unit: a prospective multicenter study. Association des R&eacute;animateurs du Centre-Ouest. Am J Respir Crit Care Med 1998; 157:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/50\">",
"      Chevron V, M&eacute;nard JF, Richard JC, et al. Unplanned extubation: risk factors of development and predictive criteria for reintubation. Crit Care Med 1998; 26:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/51\">",
"      de Lassence A, Alberti C, Azoulay E, et al. Impact of unplanned extubation and reintubation after weaning on nosocomial pneumonia risk in the intensive care unit: a prospective multicenter study. Anesthesiology 2002; 97:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/52\">",
"      Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/53\">",
"      Curry K, Cobb S, Kutash M, Diggs C. Characteristics associated with unplanned extubations in a surgical intensive care unit. Am J Crit Care 2008; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/54\">",
"      Chang LY, Wang KW, Chao YF. Influence of physical restraint on unplanned extubation of adult intensive care patients: a case-control study. Am J Crit Care 2008; 17:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/55\">",
"      Moons P, Sels K, De Becker W, et al. Development of a risk assessment tool for deliberate self-extubation in intensive care patients. Intensive Care Med 2004; 30:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/56\">",
"      Frutos-Vivar F, Ferguson ND, Esteban A, et al. Risk factors for extubation failure in patients following a successful spontaneous breathing trial. Chest 2006; 130:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/57\">",
"      Thille AW, Harrois A, Schortgen F, et al. Outcomes of extubation failure in medical intensive care unit patients. Crit Care Med 2011; 39:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/58\">",
"      Epstein SK, Ciubotaru RL, Wong JB. Effect of failed extubation on the outcome of mechanical ventilation. Chest 1997; 112:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/59\">",
"      Torres A, Gatell JM, Aznar E, et al. Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. Am J Respir Crit Care Med 1995; 152:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/60\">",
"      Rady MY, Ryan T. Perioperative predictors of extubation failure and the effect on clinical outcome after cardiac surgery. Crit Care Med 1999; 27:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38183/abstract/61\">",
"      Reyes A, Vega G, Blancas R, et al. Early vs conventional extubation after cardiac surgery with cardiopulmonary bypass. Chest 1997; 112:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1634 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-89.32.226.102-B4250248F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38183=[""].join("\n");
var outline_f37_18_38183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIOR TO EXTUBATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Airway protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Airway patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cuff leak",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXTUBATION PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POST-EXTUBATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Unplanned extubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Extubation failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1634|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21112?source=related_link\">",
"      Weaning from mechanical ventilation: Readiness testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_18_38184="Causes of vitamin D deficiency and resistance";
var content_f37_18_38184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of vitamin D deficiency and resistance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38184/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38184/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38184/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38184/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38184/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38184/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/18/38184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D has a variety of actions on calcium, phosphate, and bone metabolism. Its most important biological action is to promote enterocyte differentiation and the intestinal absorption of calcium and phosphorus, thereby promoting bone mineralization. At high vitamin D concentrations, under conditions of calcium and phosphate deficiency, it also stimulates bone resorption, thereby helping to maintain the supply of these ions to other tissues (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link&amp;anchor=H1206149#H1206149\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Calcitriol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D deficiency or resistance interferes with these processes, sometimes causing hypocalcemia and hypophosphatemia. Since hypocalcemia stimulates the release of PTH, however, the development of hypocalcemia is often masked. The secondary hyperparathyroidism, via its actions on bone and the kidney, partially corrects the hypocalcemia but enhances urinary phosphate excretion, thereby contributing to the development of hypophosphatemia and osteomalacia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=see_link&amp;anchor=H15280944#H15280944\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over the last two decades, the definition of vitamin D deficiency has varied. At present, there is no consensus on the optimal 25-hydroxyvitamin D (25OHD) concentration for skeletal and extraskeletal health. Clinicians variably consider the presence of vitamin D insufficiency at levels of 25OHD below 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    or 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (75",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    In contrast, most clinicians agree that vitamin D deficiency is present at 25OHD levels less than 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (37.5",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Adequate exposure to sunlight and fortification of dairy products with vitamin D has significantly reduced the incidence of vitamin D deficiency. However, vitamin D deficiency is still a common problem in many populations, in particular, the elderly.",
"   </p>",
"   <p>",
"    This topic will review the major causes of vitamin D deficiency and resistance. Optimal serum vitamin D concentrations, the treatment of vitamin D deficiency, and the role of vitamin D therapy for osteoporosis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .) The major causes of hypophosphatemia and hypocalcemia are also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=see_link\">",
"     \"Etiology of hypocalcemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VITAMIN D METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D (cholecalciferol) is normally synthesized in the skin under the influence of sunlight in a nonenzymatic manner. In addition, vitamin D (ergocalciferol) may be ingested from fish or plant sources. Vitamin D is then hydroxylated in the liver to 25-hydroxyvitamin D (calcidiol, 25OHD), which is the major circulating form of vitamin D and the best index of vitamin D sufficiency. Calcidiol is hydroxylated primarily in the kidney to 1,25-dihydroxyvitamin D (calcitriol, 1,25D), which is the most active form (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"     figure 1",
"    </a>",
"    ). 1,25D is also formed in some other tissues but is used only within the tissues and not circulated. Vitamin D deficiency can therefore occur as a result of decreased intake or absorption, reduced sun exposure, increased hepatic catabolism, or decreased endogenous synthesis (via decreased 25-hydroxylation in the liver or 1-hydroxylation in the kidney). End-organ resistance to vitamin D causes the equivalent result as deficiency (",
"    <a class=\"graphic graphic_table graphicRef58837 \" href=\"mobipreview.htm?37/48/38667\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NUTRITIONAL DEFICIENCY AND REDUCED CUTANEOUS SYNTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many developed countries, most vitamin D is derived from foods that are rich in the vitamin (fatty fishes) or fortified with the vitamin (milk and related products and cereals). The remainder is synthesized in the skin from 7-dehydrocholesterol under the influence of ultraviolet light, at a similar wavelength that can cause sunburn (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"     figure 1",
"    </a>",
"    ). Vitamin D deficiency can occur in people who live without sun exposure (including those whose skin is constantly protected from the sun) or whose dietary intake is low. In some individuals, however, abundant sun exposure does not preclude vitamin D insufficiency for reasons that are poorly understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, vitamin D deficiency occurs most commonly in people who live in countries distant from the equator and who consume foods that are not fortified with vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/2\">",
"     2",
"    </a>",
"    ]. Vitamin D deficiency can also occur with adequate intake if there is intestinal malabsorption of vitamin D, as occurs with celiac disease.",
"   </p>",
"   <p>",
"    Vitamin D deficiency due to reduced vitamin D intake, absorption, or cutaneous production should be considered especially in the following populations:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous vitamin D production and vitamin D stores decline with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/3\">",
"     3",
"    </a>",
"    ]. This change is most prominent in the winter. In temperate areas such as Boston and Edmonton, as an example, cutaneous production of vitamin D virtually ceases in winter, especially in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to reduced endogenous production, vitamin D intake is often low in older subjects. It has been estimated that approximately one-half of elderly women consume less than 137 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    of vitamin D, and nearly one-quarter consume less than 65 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    (recommended intake 400 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    for people 51 to 70 years old and 600 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    for people 71 years old and older) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/5\">",
"     5",
"    </a>",
"    ]. Moreover, many clinicians believe that even in those with adequate vitamin D intake, achlorhydria, which is common in the elderly, limits calcium absorption. The net effect of the many factors influencing vitamin D metabolism in the elderly is the presence of relative hypocalcemia and high serum (PTH) concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]; this secondary hyperparathyroidism can be attenuated by the administration of physiological doses of vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/8\">",
"     8",
"    </a>",
"    ]. However, older persons confined indoors may have low serum calcidiol (25OHD) concentrations even with the current recommendations for vitamin D intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary vitamin D deficiency can also occur in children, with notable differences among ethnic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/11\">",
"     11",
"    </a>",
"    ]. Among 618 Asian children in the United Kingdom, 27 percent had serum 25OHD &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/12\">",
"     12",
"    </a>",
"    ]. Serum 25OHD concentrations were correlated with ingestion of vitamin D supplements in these children, notwithstanding that increasing skin pigmentation is associated with less cutaneous vitamin D production. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Immigrants to cold climates from warm climates'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D deficiency is also a concern for lactating mothers and breast-fed infants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Healthy adults in the winter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency is also common in healthy, young adults at the end of the winter. In a study of healthy adults in the Boston area who underwent 25OHD testing at the end of winter and summer, 36 percent of 69 subjects ages 18 to 29 had vitamin D concentrations below 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     nmol/L],",
"    </span>",
"    but the prevalence decreased to 4 percent by the end of the summer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/13\">",
"     13",
"    </a>",
"    ]. Similar seasonal differences were seen in older groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 290 patients hospitalized on a general medical service, vitamin D deficiency (&lt;15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [37",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    was detected in 164 patients (57 percent), of whom 65 (22 percent) were considered severely deficient (serum concentration of 25OHD &lt;8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [20",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/14\">",
"     14",
"    </a>",
"    ]. Inadequate vitamin D intake, winter season, and housebound status were independent predictors of vitamin D deficiency. In a subgroup of 77 patients less than age 65 years without known risk factors, the prevalence of vitamin D deficiency was still 42 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Women treated for osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unrecognized vitamin D insufficiency or deficiency is also common in postmenopausal women seeking advice or receiving therapy for osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. In a study of 1536 community-dwelling postmenopausal women (evenly distributed by latitude) who were receiving osteoporosis drug therapy (bisphosphonates, raloxifene, calcitonin, or PTH), serum 25OHD concentrations were less than 20 and 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in 18 and 52 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/10\">",
"     10",
"    </a>",
"    ]. Not surprisingly, the prevalence of vitamin D insufficiency was higher in women taking less than 400 compared to &ge;400 int. units of vitamin D per day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic kidney disease (CKD) have 1,25-dihydroxyvitamin D (calcitriol) deficiency, but 25OHD deficiency may also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. This has been demonstrated in patients on dialysis and in patients with CKD pre-dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of patients with glomerular filtration rates (GFR) &lt;30 and 30 to 59",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      serum 25OHD concentrations were &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (25",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      in 14 and 26 percent, respectively, and between 10 and 30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (25 and 75",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      in 57 and 58 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 242 patients with CKD on dialysis, vitamin D deficiency (&lt;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      <span class=\"nowrap\">",
"       [37nmol/L]),",
"      </span>",
"      was evident in up to 28 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/18\">",
"       18",
"      </a>",
"      ]. Women, patients with diabetes, and patients on peritoneal dialysis were at greater risk for vitamin D deficiency. In addition, 25OHD concentrations were positively associated with bone mineral density at the lumbar spine and wrist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these associations, it is unclear if improving 25OHD concentrations benefits these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .) The Kidney Disease Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    clinical practice guidelines for bone metabolism and disease in CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/KDOQI/\">",
"     National Kidney Foundation website",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal malabsorption, associated with diseases of the small intestine, hepatobiliary tree, and pancreas, may result in decreased absorption of vitamin D",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depletion of endogenous 25OHD stores due to abnormal enterohepatic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In general, malabsorption of vitamin D occurs as a consequence of steatorrhea, which disturbs fat emulsification and chylomicron-facilitated absorption. While this may be associated with rickets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomalacia, many affected patients are asymptomatic or exhibit only a reduction in bone volume rather than evidence of defective bone mineralization.",
"   </p>",
"   <p>",
"    Adult celiac disease is a common example of a disorder in which vitamin D malabsorption occurs and in which the suspicion for vitamin D deficiency should be high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/22\">",
"     22",
"    </a>",
"    ]. These patients often present with low bone mineral density. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H21#H21\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Metabolic bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gastric bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one series of 41 obese patients who had undergone long-limb gastric bypass and 202 who had undergone short-limb bypass, the following results were seen after an average of three to five years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the end of the follow-up period, mean serum 25OHD concentrations were low in both groups, but significantly lower in the long-limb compared with the short-limb bypass group (16.8 &plusmn; 10.8",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      versus 22.7 &plusmn; 11.1",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      respectively; preoperative levels were not reported). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mean serum PTH concentrations were increased in both groups: 113.5 &plusmn;88.0 and 74.5 &plusmn; 52.7",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      in the long-limb and short-limb bypass groups (normal PTH range 12.0-65",
"      <span class=\"nowrap\">",
"       pg/mL).",
"      </span>",
"      Some patients in the short-limb bypass group had evidence of secondary hyperparathyroidism in spite of normal 25OHD concentrations (&ge;30",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      suggestive of selective calcium malabsorption. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=see_link&amp;anchor=H11#H11\">",
"       \"Medical management of patients after bariatric surgery\", section on 'Nutritional deficiencies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, patients with cholestatic liver disease, extrahepatic biliary obstruction and diseases of the distal portions of the small intestine, such as regional enteritis, may develop vitamin D deficiency not only secondary to poor vitamin D absorption but disruption of enterohepatic circulation, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D deficiency may also develop in patients who have had partial or total gastrectomy for peptic ulcer disease, bariatric surgery or other indications. Loss of gastrointestinal acidity or malfunction of the proximal small bowel underlies the vitamin D malabsorption in such circumstances. Absence of sufficient absorbing surface or failure of intestinal mucosal cells to respond to vitamin D or its metabolites may also cause vitamin D malabsorption.",
"   </p>",
"   <p>",
"    Metabolic bone disease associated with gastrointestinal disorders is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=see_link\">",
"     \"Metabolic bone disease in inflammatory bowel disease\"",
"    </a>",
"    .) The American Gastroenterological Association (AGA) technical review and guideline for osteoporosis in gastrointestinal diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     AGA website",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immigrants to cold climates from warm climates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency has been reported in dark-skinned immigrants from warm climates to cold climates in North America and Europe. Asian Indian immigrants to the United States may have vitamin D deficiency even with what is considered adequate sun exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Patients who have musculoskeletal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific musculoskeletal pain is a common symptom of vitamin D deficiency and the prevalence of unrecognized vitamin D deficiency among patients with these symptoms is extremely high. As an example, in a study of 150 subjects with persistent, nonspecific musculoskeletal pain presenting to an inner city health clinic in Minneapolis, 93 percent were vitamin D deficient (serum 25OHD concentration &le;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)),",
"    </span>",
"    and 28 percent of all patients had severe deficiency (concentration &le;8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     nmol/L))",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, patients who present with nonspecific musculoskeletal pain should be screened for vitamin D deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced cystic fibrosis are usually deficient in vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/28\">",
"     28",
"    </a>",
"    ], and they require more than the usual recommended dose for young adults (eg, more than 400 int.",
"    <span class=\"nowrap\">",
"     units/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link&amp;anchor=H14#H14\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Musculoskeletal disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Extensive burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a history of extensive burn injuries, vitamin D synthesis in skin is below normal, even with sun exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DEFICIENCY RELATED TO ABNORMAL SYNTHESIS AND CATABOLISM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Calcidiol (25-hydroxyvitamin D)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcidiol deficiency can result from decreased synthesis in the liver, increased catabolism, or renal loss of calcidiol bound to vitamin D-binding protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Decreased synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since vitamin D is hydroxylated in the liver to produce calcidiol (25OHD), patients with severe parenchymal or obstructive hepatic disease may have reduced production of this metabolite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. The majority of the liver must be dysfunctional before calcidiol synthesis is reduced. Thus, these patients rarely manifest biochemical or histological evidence of osteomalacia unless concomitant nutritional deficiency or interruption of the enterohepatic circulation occurs (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased circulating levels of calcidiol may also occur in patients treated with drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , due to induction of P-450 enzyme activity, which metabolizes calcidiol to inactive vitamin D metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Supplementation with vitamin D (400 to 4000 int.",
"    <span class=\"nowrap\">",
"     units/day;",
"    </span>",
"    1 mcg = 40 int. units) may be necessary to prevent vitamin D deficiency in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36969?source=see_link&amp;anchor=H8#H8\">",
"     \"Antiepileptic drugs and bone disease\", section on 'Effect of AED type'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36969?source=see_link&amp;anchor=H19#H19\">",
"     \"Antiepileptic drugs and bone disease\", section on 'Calcium and vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Renal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the calcidiol in serum is bound to vitamin D-binding protein. Patients with the nephrotic syndrome can excrete enough vitamin D-binding protein (with calcidiol bound to it) to become vitamin D-deficient, and may develop hypocalcemia and hypophosphatemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Calcitriol (1,25-dihydroxyvitamin D)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final step in the metabolic activation of vitamin D is 1-hydroxylation of calcidiol in the proximal convoluted tubule cells of the kidney to produce calcitriol (1,25-dihydroxyvitamin D) (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"     figure 1",
"    </a>",
"    ). This reaction is stimulated by PTH, calcitonin and hypophosphatemia, and inhibited by calcium, 1,25-dihydroxyvitamin D, and hyperphosphatemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The substrate for 1-hydroxylation is incorporated into the kidney following glomerular filtration of the 25-hydroxyvitamin D linked to its binding protein and megalin-directed transfer of the substrate into the renal proximal convoluted tubule cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with renal failure, calcitriol (1,25 dihydroxyvitamin D) production is low due to diminished glomerular filtration, loss of the 1-alpha-hydroxylase enzyme secondary to structural renal compromise, and suppression of enzyme activity secondary to hyperphosphatemia. The net result is a tendency to hypocalcemia, hyperparathyroidism, and bone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Vitamin D dependent rickets type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D-dependent rickets type I is also known as pseudovitamin D-deficient rickets because the clinical and biochemical evidence of rickets can be corrected with 1,25-dihydroxyvitamin D (calcitriol) treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This form of rickets is due to an inactivating mutation in the 1-hydroxylase gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. As a result, calcidiol is not hydroxylated to calcitriol, and calcium is not absorbed normally. As a result of the hypocalcemia, parathyroid hormone levels rise, resulting in an increase in urinary excretion of amino acids and phosphate. In addition to these biochemical abnormalities, within the first year of life, patients exhibit muscle weakness and hypotonia, motor retardation, and stunted growth. With progression, patients develop the classic radiographic signs of vitamin D deficiency rickets and bone biopsy evidence of osteomalacia. This disorder, as well as other types of rickets, is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     VITAMIN D RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;What had been called type 2 vitamin D-dependent rickets is actually a form of vitamin D resistance and is now known as hereditary vitamin D-resistant rickets (HVDRR). HVDRR, an autosomal recessive disorder, is a very rare form of rickets, with fewer than 50 known affected kindreds. It is associated with end&ndash;organ resistance to calcitriol usually caused by mutations in the gene encoding the vitamin D receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/38,42-48\">",
"     38,42-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical spectrum varies widely, probably reflecting the type of mutation within the vitamin D receptor and the amount of residual vitamin D receptor activity. Affected children usually appear normal at birth but develop rickets within the first two years of life (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53635 \" href=\"mobipreview.htm?12/45/13022\">",
"     image 1",
"    </a>",
"    ). A peculiar feature of the syndrome is alopecia, which appears in approximately two-thirds of cases and is a marker of disease severity. Alopecia results from the lack of vitamin D receptor action within keratinocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Additional ectodermal anomalies may also be seen including multiple milia, epidermal cysts, and oligodontia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Hereditary vitamin D resistant rickets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identified mutations or defects in the vitamin D receptor include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure of 1,25(OH)2D binding to available receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A reduction in 1,25(OH)2D receptor binding sites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal binding affinity of 1,25(OH)2D to receptor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inadequate translocation of 1,25(OH)2D-receptor complex to the nucleus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diminished affinity of the 1,25(OH)2D-receptor complex for the DNA binding domain secondary to changes in the structure of receptor zinc binding fingers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38184/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of HVDRR is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Hereditary vitamin D resistant rickets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/45/10962?source=see_link\">",
"       \"Patient information: Vitamin D deficiency (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/62/15331?source=see_link\">",
"       \"Patient information: Vitamin D deficiency (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency can be caused by several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired availability of vitamin D, secondary to inadequate dietary vitamin D, malabsorptive disorders,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diminished cutaneous synthesis",
"     </li>",
"     <li>",
"      Impaired hydroxylation by the liver to produce 25-hydroxyvitamin D",
"     </li>",
"     <li>",
"      Increased hepatic catabolism of 25-hydroxyvitamin D",
"     </li>",
"     <li>",
"      Impaired kidney production of 1,25-dihydroxyvitamin D",
"     </li>",
"     <li>",
"      Renal loss of vitamin D and vitamin D binding proteins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    End organ insensitivity (resistance) to vitamin D metabolites is rare. Hereditary vitamin D-resistant rickets (HVDRR) is associated with end&ndash;organ resistance to calcitriol due most often to mutations in the gene encoding the vitamin D receptor. The treatment of this rare disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of vitamin D deficiency is particularly high in the elderly, due to an age-associated decline in cutaneous vitamin D production and decreased dietary vitamin D intake. Individuals with limited sun exposure and malabsorptive gastrointestinal disease are also at risk.",
"   </p>",
"   <p>",
"    Other aspects of vitamin D deficiency, including its treatment, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link&amp;anchor=H11#H11\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Vitamin D'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/1\">",
"      Binkley N, Novotny R, Krueger D, et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab 2007; 92:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/2\">",
"      Lamberg-Allardt CJ, Outila TA, K&auml;rkkainen MU, et al. Vitamin D deficiency and bone health in healthy adults in Finland: could this be a concern in other parts of Europe? J Bone Miner Res 2001; 16:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/3\">",
"      Tsai, KS, Wahner HW, Offord KP, et al. Effect of aging on vitamin D stores and bone density in women. Calcif Tissue Int 1987; 40:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/4\">",
"      Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/5\">",
"      MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985; 76:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/6\">",
"      Harris SS, Soteriades E, Coolidge JA, et al. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 2000; 85:4125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/7\">",
"      Passeri G, Pini G, Troiano L, et al. Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab 2003; 88:5109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/8\">",
"      Krall EA, Sahyoun N, Tannenbaum S, et al. Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N Engl J Med 1989; 321:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/9\">",
"      Gloth FM 3rd, Gundberg CM, Hollis BW, et al. Vitamin D deficiency in homebound elderly persons. JAMA 1995; 274:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/10\">",
"      Holick MF, Siris ES, Binkley N, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90:3215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/11\">",
"      Callaghan AL, Moy RJ, Booth IW, et al. Incidence of symptomatic vitamin D deficiency. Arch Dis Child 2006; 91:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/12\">",
"      Lawson M, Thomas M. Vitamin D concentrations in Asian children aged 2 years living in England: population survey. BMJ 1999; 318:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/13\">",
"      Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002; 112:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/14\">",
"      Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/15\">",
"      Guardia G, Parikh N, Eskridge T, et al. Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis: a five-year cross-sectional study with public health implications. Osteoporos Int 2008; 19:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/16\">",
"      LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/17\">",
"      Taskapan H, Ersoy FF, Passadakis PS, et al. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol 2006; 66:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/18\">",
"      Elder GJ, Mackun K. 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res 2006; 21:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/19\">",
"      Compston JE. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut 1986; 27:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/20\">",
"      Dibble JB, Sheridan P, Losowsky MS. A survey of vitamin D deficiency in gastrointestinal and liver disorders. Q J Med 1984; 53:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/21\">",
"      Kumar R. Hepatic and intestinal osteodystrophy and the hepatobiliary metabolism of vitamin D. Ann Intern Med 1983; 98:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/22\">",
"      Shaker JL, Brickner RC, Findling JW, et al. Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 1997; 157:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/23\">",
"      Johnson JM, Maher JW, DeMaria EJ, et al. The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg 2006; 243:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/24\">",
"      Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/25\">",
"      American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/26\">",
"      Awumey EM, Mitra DA, Hollis BW, et al. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. J Clin Endocrinol Metab 1998; 83:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/27\">",
"      Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/28\">",
"      Donovan DS Jr, Papadopoulos A, Staron RB, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 1998; 157:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/29\">",
"      Klein GL, Chen TC, Holick MF, et al. Synthesis of vitamin D in skin after burns. Lancet 2004; 363:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/30\">",
"      Hahn TJ. Drug-induced disorders of vitamin D and mineral metabolism. Clin Endocrinol Metab 1980; 9:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/31\">",
"      Sotaniemi EA, Hakkarainen HK, Puranen JA, Lahti RO. Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy. Ann Intern Med 1972; 77:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/32\">",
"      V&auml;lim&auml;ki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994; 9:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/33\">",
"      Kovacs CS, Jones G, Yendt ER. Primary hyperparathyroidism masked by antituberculous therapy-induced vitamin D deficiency. Clin Endocrinol (Oxf) 1994; 41:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/34\">",
"      Fortenbery EJ, McDermott MT, Duncan WE. Effect of theophylline on calcium metabolism and circulating vitamin D metabolites. J Bone Miner Res 1990; 5:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/35\">",
"      Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991; 78:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/36\">",
"      Goldstein DA, Haldimann B, Sherman D, et al. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1981; 52:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/37\">",
"      Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/38\">",
"      Malloy PJ, Feldman D. Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am 2010; 39:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/39\">",
"      Wang X, Zhang MY, Miller WL, Portale AA. Novel gene mutations in patients with 1alpha-hydroxylase deficiency that confer partial enzyme activity in vitro. J Clin Endocrinol Metab 2002; 87:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/40\">",
"      Kitanaka S, Takeyama K, Murayama A, Kato S. The molecular basis of vitamin D-dependent rickets type I. Endocr J 2001; 48:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/41\">",
"      Kato S. Genetic mutation in the human 25-hydroxyvitamin D3 1alpha-hydroxylase gene causes vitamin D-dependent rickets type I. Mol Cell Endocrinol 1999; 156:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/42\">",
"      Li YC, Pirro AE, Amling M, et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A 1997; 94:9831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/43\">",
"      Whitfield GK, Selznick SH, Haussler CA, et al. Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. Mol Endocrinol 1996; 10:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/44\">",
"      Brooks MH, Bell NH, Love L, et al. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 1978; 298:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/45\">",
"      Yagi H, Ozono K, Miyake H, et al. A new point mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab 1993; 76:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/46\">",
"      Malloy PJ, Weisman Y, Feldman D. Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. J Clin Endocrinol Metab 1994; 78:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/47\">",
"      Rut AR, Hewison M, Kristjansson K, et al. Two mutations causing vitamin D resistant rickets: modelling on the basis of steroid hormone receptor DNA-binding domain crystal structures. Clin Endocrinol (Oxf) 1994; 41:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/48\">",
"      Malloy PJ, Eccleshall TR, Gross C, et al. Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest 1997; 99:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/49\">",
"      Sakai Y, Kishimoto J, Demay MB. Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J Clin Invest 2001; 107:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/50\">",
"      Chen CH, Sakai Y, Demay MB. Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia. Endocrinology 2001; 142:5386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/51\">",
"      Malloy PJ, Wang J, Srivastava T, Feldman D. Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. Mol Genet Metab 2010; 99:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/52\">",
"      Forghani N, Lum C, Krishnan S, et al. Two new unrelated cases of hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from the same novel nonsense mutation in the vitamin D receptor gene. J Pediatr Endocrinol Metab 2010; 23:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38184/abstract/53\">",
"      Hewison M, Rut AR, Kristjansson K, et al. Tissue resistance to 1,25-dihydroxyvitamin D without a mutation of the vitamin D receptor gene. Clin Endocrinol (Oxf) 1993; 39:663.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2048 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-75F91836D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38184=[""].join("\n");
var outline_f37_18_38184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VITAMIN D METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NUTRITIONAL DEFICIENCY AND REDUCED CUTANEOUS SYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Healthy adults in the winter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Women treated for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immigrants to cold climates from warm climates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Patients who have musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Extensive burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DEFICIENCY RELATED TO ABNORMAL SYNTHESIS AND CATABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Calcidiol (25-hydroxyvitamin D)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Decreased synthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Renal loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Calcitriol (1,25-dihydroxyvitamin D)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Vitamin D dependent rickets type I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      VITAMIN D RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2048\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2048|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/45/13022\" title=\"diagnostic image 1\">",
"      Vit D deficiency rickets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2048|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/23/20862\" title=\"figure 1\">",
"      Vit D metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2048|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/48/38667\" title=\"table 1\">",
"      Causes of vitamin D deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36969?source=related_link\">",
"      Antiepileptic drugs and bone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/62/15331?source=related_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/45/10962?source=related_link\">",
"      Patient information: Vitamin D deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_18_38185="School readiness";
var content_f37_18_38185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   School readiness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38185/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38185/contributors\">",
"     Lynnette L Harris, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38185/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38185/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38185/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38185/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/18/38185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kindergarten entry, the beginning of a child's formal education, is an important developmental milestone. Early school success or failure can affect the child's well-being, self-esteem, and motivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/1\">",
"     1",
"    </a>",
"    ]. Because early learning experiences influence the manner in which a child relates to others during the course of his or her life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], it is important to try to ensure that the child begins school when he or she is developmentally ready to participate in classroom activities with the greatest likelihood of success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The idea that all children should start school \"ready to learn\" was part of the Goals 2000: Educate America Act enacted by the United States Congress in 1994 and is the first stated goal of the National Educational Goals Panel (NEGP) (",
"    <a class=\"external\" href=\"file://govinfo.library.unt.edu/negp/page3.htm\">",
"     govinfo.library.unt.edu/negp/page3.htm",
"    </a>",
"    ), which was established in 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The idea of \"school readiness\" has traditionally implied that there is a measurable standard against which a given child's physical, intellectual, and socioemotional functioning can be compared, and that meeting the standard predicts future academic success. Such is not the case. Empiric evidence of such readiness standards does not exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/4\">",
"     4",
"    </a>",
"    ], nor is there a consensus among educators about what constitutes readiness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of consensus regarding readiness, a national survey of kindergarten teachers reported that 35 percent of their students were not ready to \"participate successfully in school\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/9\">",
"     9",
"    </a>",
"    ]. Problems identified by the teachers that affected school readiness included deficiencies in language, emotional maturity, general knowledge, social confidence, moral awareness, and physical well-being, in decreasing order of importance.",
"   </p>",
"   <p>",
"    Virtually every child, regardless of physical or mental disabilities, cultural or ethnic background, or prior exposure to educational activities, is capable of learning to some extent and should participate in an educational program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/10\">",
"     10",
"    </a>",
"    ]. According to the American Academy of Pediatrics (AAP) Committee on School Health and Committee on Early Childhood, Adoption and Dependent Care, \"all children are entitled to education in an environment where the great variability in early childhood development is understood and supported\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will broadly discuss factors that affect a child's ability to learn and will describe aspects of family, school, and community systems that support the child's ability to achieve his or her maximal educational potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS RELATED TO A CHILD'S ABILITY TO LEARN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various sociodemographic factors affect a child's ability to learn and his or her risk for school problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Although it is not the only factor, lack of readiness contributes to early grade retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/13\">",
"     13",
"    </a>",
"    ]. Approximately 8 percent of children repeat kindergarten or first grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Health and social factors related to early school failure among the general population were studied among a nationally representative sample of nearly 10,000 US children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/14\">",
"     14",
"    </a>",
"    ]. In a logistic regression analysis, variables that were independently associated with increased risk of grade retention included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poverty (odds ratio [OR] 1.7, 95% CI 1.4-2.1)",
"     </li>",
"     <li>",
"      Male gender (OR 1.5, 95% CI 1.3-1.9)",
"     </li>",
"     <li>",
"      Low maternal education (OR 1.4, 95% CI 1.1-1.8)",
"     </li>",
"     <li>",
"      Speech defects (OR 1.7, 95% CI 1.1-2.6)",
"     </li>",
"     <li>",
"      Low birth weight (OR 1.6, 95% CI 1.2-2.2)",
"     </li>",
"     <li>",
"      Enuresis (OR 1.6, 95% CI 1.1-2.2)",
"     </li>",
"     <li>",
"      Exposure to household smoking (OR 1.4, 95% CI 1.1-1.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings indicate that social factors, particularly poverty, play an important role in school success and failure.",
"   </p>",
"   <p>",
"    Between 32 and 50 percent of preschoolers have at least one risk factor for learning difficulties, and approximately 15 percent have more than one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. Exposure to multiple risk factors increases the probability of development of socioemotional problems, which adversely affect school performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2,16,17\">",
"     2,16,17",
"    </a>",
"    ]. The combination of risk factors, rather than any single factor, best predicts the child's socioemotional functioning and academic performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/18\">",
"     18",
"    </a>",
"    ]. Additional risk factors for socioemotional problems include parental depression (particularly maternal depression), substance abuse, domestic violence, homelessness, psychiatric disturbance, and exposure to repeated major life stressors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2,19\">",
"     2,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although children can be resilient or have families that buffer them from adverse effects, it is important to recognize the risk factors mentioned above, since early recognition may permit intervention before school problems are evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2,12,20-25\">",
"     2,12,20-25",
"    </a>",
"    ]. Identification of problems in a school-age child should prompt prevention efforts in preschool-age siblings.",
"   </p>",
"   <p>",
"    Research on protective factors is less well developed than that on risk factors but suggests a continuum of protective effects, which are more or less powerful depending upon the combination. In the study described above, factors that were independently associated with decreased risk of retention included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High maternal education (OR 0.6, 95% CI 0.4-0.9)",
"     </li>",
"     <li>",
"      Residence with both biologic parents at six years of age (OR 0.7, 95% CI 0.6-0.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study, children who participated in Head Start showed better literacy (which in turn predicts school success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]) than age-matched peers who did not participate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/28\">",
"     28",
"    </a>",
"    ]. The two groups were similar with respect to behavioral and health problems. Head Start is a national preschool education program designed to prepare children from disadvantaged backgrounds for entrance into formal education (",
"    <a class=\"external\" href=\"file://www.acf.hhs.gov/programs/ohs/\">",
"     www.acf.hhs.gov/programs/ohs/",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Resilience can be promoted through the development of school-related competencies (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Readiness of the child'",
"    </a>",
"    below), which include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early education experiences (eg, early intervention and Head Start programs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/30-33\">",
"       30-33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Parental involvement in early learning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Early peer relationships",
"     </li>",
"     <li>",
"      Culturally compatible classroom programs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of 16 studies of the effectiveness of early childhood development programs in the US found that such programs improve IQ and academic achievement test scores, and are associated with decreased grade retention and placement in special education classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/33\">",
"     33",
"    </a>",
"    ]. Another systematic review had similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, economic studies have demonstrated positive cost-benefit yields of early intervention programs. A study conducted in California showed a $7000 net current value benefit per child, equaling a two- to three-fold return on every $1 invested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/37\">",
"     37",
"    </a>",
"    ]. Another study conducted in Minnesota showed a return of 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/38\">",
"     38",
"    </a>",
"    ], reflecting a better than 8:1 cost-benefit ratio over the life of an individual child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protective factors described above exist primarily within the child's environment and particularly within the parent-child relationship, rather than within the child's innate intellectual capacity. This observation provides the rationale for the recommendations regarding community support systems described below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Family and community supports'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPONENTS OF READINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of school readiness is multifaceted. The National Education Goals Panel (NEGP) described three essential components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Readiness of the child",
"     </li>",
"     <li>",
"      Readiness of the school system",
"     </li>",
"     <li>",
"      Family and community supports that contribute to the child's readiness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendations of the NEGP, although endorsed by federal and state governments, have not been fully implemented (particularly those that relate to readiness of schools and community support systems). Nonetheless, there are steps that families and health care providers can take to ensure that their children and patients, respectively, are adequately prepared to enter school \"ready to learn\". These steps are described below. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Readiness of the child'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Promotion of school readiness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     READINESS OF THE CHILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, readiness of a child to attend school referred to the child's level of cognitive functioning and focused specifically on whether or not the child had sufficiently mastered certain academic skills. However, kindergarten teachers often feel the purpose of kindergarten is to teach those very skills. Still, children who have mastered such rudimentary skills as counting with one-to-one correspondence, recognizing numbers and letters, and mastering quantitative and relational concepts (eg, bigger than, equal to) are more likely to learn to read and do math earlier and better than children who do not possess those skills at kindergarten entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/42\">",
"     42",
"    </a>",
"    ]. Although mastery of cursory academics is important, the scope of the child's readiness has been expanded by the National Educational Goals Panel (NEGP) to include a total of five domains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/16,41\">",
"     16,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical well-being and motor development",
"     </li>",
"     <li>",
"      Social and emotional development",
"     </li>",
"     <li>",
"      Child's approach to learning",
"     </li>",
"     <li>",
"      Language development",
"     </li>",
"     <li>",
"      Cognition and general knowledge",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The five domains of the child's readiness for school are interrelated and overlap to some degree. The child's readiness is no longer defined by whether he or she has mastered specific skills; rather, it is viewed as a complex network of development that spans physical, cognitive, social, and community functioning.",
"   </p>",
"   <p>",
"    There is variation among children with respect to the domains that are mastered before kindergarten entry. In part, these differences are related to early experiences, such as enrollment in quality day care, cultural environments that emphasize varying behaviors and activities, inborn",
"    <span class=\"nowrap\">",
"     developmental/physical",
"    </span>",
"    characteristics, and family risk factors. Even children with seemingly inadequate school readiness skills are capable of acquiring some new skills while in kindergarten. However, children with a solid base of school readiness skills appear to learn more, and to learn more quickly, than children without that foundation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical well-being",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical well-being and motor development of children varies depending upon their health status, growth, physical abilities and disabilities, and prenatal, perinatal, and postnatal conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/43\">",
"     43",
"    </a>",
"    ]. Although normal physical fitness helps the child to pay attention and participate in social and academic activities, impaired physical or motor development does not prevent the child from entering school. It may, however, affect the child's ability to perform school-related activities and should be considered when making educational programming and service decisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=see_link\">",
"     \"Support services for the care of chronically ill children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27737?source=see_link&amp;anchor=H7#H7\">",
"     \"Children with special health care needs\", section on 'Development/learning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of conditions that affect physical well-being and, consequently, school program or service planning include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic or congenital disorders (eg, Down syndrome) may require remedial instruction or therapy (eg, speech and language therapy, physical therapy, occupational therapy) as adjuncts to the school program.",
"     </li>",
"     <li>",
"      Delayed gross or fine motor development may require physical therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occupational therapy in order to improve skills necessary for exploration of the environment, engagement in social activities, and paper-and-pencil tasks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vision or hearing impairment must be addressed before entering school.",
"     </li>",
"     <li>",
"      Impaired oral-motor skills may require speech and language therapy to improve ability to participate in academic activities and develop social interaction skills with peers.",
"     </li>",
"     <li>",
"      Chronic medical conditions (eg, asthma, sickle cell disease, food allergies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/45\">",
"       45",
"      </a>",
"      ]) require optimal medical therapy to minimize acute exacerbations that could lead to school absence. Children with these conditions may also require a plan to receive medications or emergent medical therapy at school. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=see_link\">",
"       \"Food allergy in schools and camps\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poor sleep hygiene may affect school readiness and performance. Among a group of seemingly normal kindergartners (none of whom had been identified as having a sleep disturbance), children with inadequate school readiness who were not going to progress to first grade were more likely to have longer sleep latencies, reduced sleep efficiency, increased nocturnal awakenings, and daytime sleepiness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As illustrated above, the physical well-being of a child can affect his or her early learning experiences. Children who deviate significantly from normative expectations may need special services or alterations in the school program in order to maximize their learning potential.",
"   </p>",
"   <p>",
"    At every visit from infancy through the preschool years, pediatric health care providers should be mindful of health conditions that affect the ability of their patients to learn. This includes regular screening for developmental problems, socioemotional risk factors, vision and hearing problems, and various medical conditions (eg, lead poisoning, iron deficiency anemia, delayed immunizations). (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28744564\">",
"    <span class=\"h2\">",
"     Social and emotional development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The social and emotional development of the child encompasses his or her self-concept as well as interpersonal skills. Socioemotional competency also influences cognitive development and pre-academic skills",
"    <em>",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emotional development is a function of breadth and depth of emotions (eg, joy, anger, sadness, pride, shame, guilt, etc) that have been experienced by the child, the manner in which the emotions are expressed, and whether or not the child manifests sensitivity to and empathy for other people.",
"     </li>",
"     <li>",
"      Social development reflects the child's capacity for forming reciprocal relationships with peers and adults, including the ability to create opportunities for sharing and the ability to consider another person's perspective. A child's ability to interact well with peers is one of the most salient predictors of adult adaptation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40,49\">",
"       40,49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific socioemotional competencies include self-regulation and the ability to separate from parents, the ability to express emotions in an appropriate manner, positive self-efficacy, awareness of the effect of one&rsquo;s actions on others, comprehension of the perspective of others, and a variety of prosocial behaviors (eg, taking turns, sharing, helping, acceptance of differences, empathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40,50\">",
"     40,50",
"    </a>",
"    ]. It is also important to be able to form and maintain relationships with others, which requires the ability to interact cooperatively and respectfully, to recognize the intent of underlying actions, and to offer and seek out support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40\">",
"     40",
"    </a>",
"    ]. Some of these skills, including self-regulation, adaptive behavior, interpersonal skills, and attention, can be improved through experience and training in the classroom setting as well as in primary care centers and at home (",
"    <a class=\"graphic graphic_table graphicRef54909 \" href=\"mobipreview.htm?8/17/8476\">",
"     table 1C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2,48,51-53\">",
"     2,48,51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Socioemotional functioning is a better predictor of academic performance in early grades than are cognitive abilities or family characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Teachers are less likely to recognize cognitive competencies in children who exhibit \"undesirable\" behavior (eg, verbal and physical aggression, impulsive behavior, lack of cooperation, ignoring or disregarding others, oppositional or defiant behavior) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2\">",
"     2",
"    </a>",
"    ]. Such children also have limited opportunities to learn from their peers, since the peers are likely to reject them as friends on account of the undesirable behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Early Childhood Longitudinal Survey (ECLS) gathered data from a nationally representative sample of more than 22,000 kindergarten children, with teachers rating various behavior problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/59\">",
"     59",
"    </a>",
"    ]. The ECLS data suggested that approximately 10 percent of children enrolled in an average kindergarten classroom engage \"often\" or \"very often\" in negative behavior such as arguing or fighting. A study examining ratings of Head Start teachers in particular noted that nearly 40 percent of their pupils exhibit at least one disruptive and unsafe behavior each day (eg, kicking, hitting, threatening), and 10 percent exhibit at least six instances of such behaviors per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. A review of prevalence studies within Head Start programs found variation in expression of problem behavior, ranging from 5 to 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/62\">",
"     62",
"    </a>",
"    ]. Preschool teachers and child care providers in two additional surveys reported that the single greatest challenge they face is disruptive behavior and that the problem seems to be increasing over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Approach to learning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child's approach to learning refers to the strategies he or she adopts to acquire, use, and demonstrate skills or knowledge.",
"   </p>",
"   <p>",
"    Children approach learning through a combination of predispositions and learning styles. \"Predispositions\" are inborn or instilled at a very early age and refer to such factors as the child's gender, temperament, cultural patterns, and values. &ldquo;Learning style&rdquo; refers to the child's method of responding across situations, and includes such factors as curiosity, initiative, attention, persistence, reflection, imagination, and reasoning. Children are most likely to be academically successful when teaching styles match their learning styles, yet standard school curricula often favor one style over others (eg, visual rather than auditory) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40\">",
"     40",
"    </a>",
"    ]. Encouraging a particular learning style without considering an individual child's needs or cultural background may put children with alternate learning styles at a disadvantage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kindergarten teachers describe most students, even the ones most at risk for poor school readiness, as exhibiting positive approaches to classroom learning. That is, even in high-risk groups, the children tend to demonstrate eagerness to master new skills, reasonable attention, and persistence in completing activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Language development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Language development includes verbal language skills such as listening, speech, and vocabulary, as well as emerging literacy skills such as sound-symbol association and understanding that stories have a beginning, middle, and end [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/41\">",
"     41",
"    </a>",
"    ]. The timing of language deficits appears to be more important than the persistence of them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/64\">",
"     64",
"    </a>",
"    ]. The presence of language problems immediately before kindergarten entry (ie, at 4.5 years of age) was highly correlated with decreased school readiness, whereas early language problems that had seemingly resolved did not have an adverse impact on school readiness. Receptive language problems were a stronger predictor of inadequate school readiness than expressive language problems. Delayed language development is the most common reason identified by kindergarten teachers for lack of readiness among kindergarten students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/9\">",
"     9",
"    </a>",
"    ]. Parents can promote the development of language skills in their children by reading with them daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/65-68\">",
"     65-68",
"    </a>",
"    ], reviewing linguistic concepts, helping them to identify the sound patterns, and helping them to understand and re-tell stories (",
"    <a class=\"graphic graphic_table graphicRef74888 \" href=\"mobipreview.htm?8/26/8621\">",
"     table 1B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10599?source=see_link\">",
"     \"Emergent literacy including language development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children use language not only for basic communication but also to access information in their knowledge stores. Thus, language is crucial for conceptual development and reasoning. Language development is strongly associated with conventional definitions of academic success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40\">",
"     40",
"    </a>",
"    ]. However, this notion of academic success has limited applicability for the non-English-dominant child, an issue that is of increasing importance as societal demographics continue to evolve.",
"   </p>",
"   <p>",
"    Language development is closely interwoven with socioemotional development. The use of language requires agreement about the ways in which words are used and the structure of communication within a group. Most of a child's language development occurs through his or her interaction with other people, particularly parents and caregivers, who often provide bridges in early communication efforts (eg, asking questions to help clarify the child's expressions).",
"   </p>",
"   <p>",
"    The way in which children acquire and use language varies between cultural groups; even within a single sociocultural group, the rate of language acquisition varies considerably [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, the language of an individual child may vary depending upon the setting. By the time they enter school, children have developed language functions within the background of their home and community environments; thus, a child's language skills are embedded in his or her cultural background. If that cultural background involves experiences discrepant from typical school experiences, the child may have more difficulty using his or her language abilities in school. Educators and parents should be sensitive to such struggles.",
"   </p>",
"   <p>",
"    Literacy begins to develop before the child learns how to read; it includes the idea of assigning meaning to symbols, as well as how to listen and remember. Early exposure to books and reading is highly beneficial, although exposure to words can occur in other ways (eg, street signs, television, clothing labels, etc). Simple participation in routine activities contributes to language development. As an example, during make-believe activities, children are exposed to the process of structuring stories by role-playing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General knowledge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognition and general knowledge involve the recognition that different objects have various characteristics (eg, color, shape, size, number, and spatial relations) and the ability to make comparative distinctions on the basis of those characteristics. It also includes being familiar with conventions of print (in English, reading top to bottom) and understanding sound-symbol associations. Parents can promote cognitive and general knowledge skills through various activities at home and in the community (",
"    <a class=\"graphic graphic_table graphicRef70285 \" href=\"mobipreview.htm?31/62/32748\">",
"     table 1A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the past, cognitive ability (ie, intelligence) was the primary, if not sole, indicator of school readiness, and social conventional knowledge (eg, ability to name colors and count) was the predominant area of skill development. Cognitive ability continues to be the domain that is most commonly associated with school readiness, particularly by parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the NEGP's view of this domain encompasses all types of knowledge: physical, logico-mathematical, and social-conventional.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical knowledge refers to the recognition that objects have physical properties in an external reality. The properties can be learned through observation and experience. In handling a ball, for example, one learns that it has weight and size, and rolls downward when placed on an incline.",
"     </li>",
"     <li>",
"      Logico-mathematical knowledge refers to the relationships and associations individuals create in their minds between and among objects: for example, perceiving two objects to be different because of variance in a particular physical property (eg, color, size). Logico-mathematical knowledge is difficult to assess because of its complexity, but understanding relationships is integral to problem solving.",
"     </li>",
"     <li>",
"      Social-conventional knowledge refers to school-learned, society-endorsed \"facts\" that are maintained across generations. For example, use of a Judeo-Christian calendar system, agreeing that the English language is comprised of 26 letters, and that the color of the daytime sky usually is \"blue,\" whereas the sun is \"yellow.\" Social-conventional knowledge is the type of knowledge on which the assessment of a child's cognitive capabilities is typically focused, even though it has the greatest variation across cultural groups and is the easiest to acquire.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three types of knowledge are interrelated yet distinct. Children must develop a classification system that discriminates objects before they can \"read\" the physical properties. They may be able to count by rote to 10, but if they do not understand one-to-one correspondence, they will be unable to say how many blocks are in a stack.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronologic age",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to enroll in kindergarten, children must reach their fifth birthday by a date that is arbitrarily set by the school system, usually the first day of September or October [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558613169\">",
"    <span class=\"h3\">",
"     Delayed or early enrollment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For typically developing children, neither delayed nor early entrance into kindergarten has been shown to yield substantial differences in academic skill development after the first few years of school. However, both deviations from the norm increase the likelihood of subsequent psychosocial struggles.",
"   </p>",
"   <p>",
"    Empiric evidence supports the enrollment of children in kindergarten at the age-appropriate time (which varies to some degree by school district). If there is concern about a child's ability to successfully participate in kindergarten, parents, teachers, and health care providers should carefully consider the potential benefit and detriment that can arise from either course of action, and if the decision is to proceed with enrollment, they should communicate frequently during the first weeks of school to determine whether special programming or services are necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Delayed enrollment",
"      </strong>",
"      &ndash; Parents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      teachers may advocate delaying kindergarten enrollment for some children who are deemed to be \"unready.\" This is particularly true of boys who have birthdays that are near the cut-off date. This practice is based on an assumption that the child needs more time to develop basic cognitive or psychosocial skills.",
"      <br/>",
"      <br/>",
"      However, waiting an extra year does not yield any noticeable benefit, particularly if the child remains in the environment where readiness was not fostered. In fact, for attainment of basic academic skills, (eg, sound-symbol awareness, letter and number recognition, counting) the effects of schooling outweigh the effects of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/70\">",
"       70",
"      </a>",
"      ]. Children who postpone kindergarten enrollment for one year do not perform any better than children who entered kindergarten at the usual age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/71\">",
"       71",
"      </a>",
"      ]. Academic performance and social abilities of students who enrolled at five years of age and those who delayed enrollment are similar after first or second grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/72-76\">",
"       72-76",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Moreover, students who are older than classmates are more likely to drop out of school in later grades than their age-appropriate peers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. The causality of this association has not been established; the high drop-out rate may be related to factors that contributed to delayed enrollment, rather than delayed enrollment itself. Students older than their classroom peers also have more parent-reported behavior problems and youth-reported health-risk behaviors (eg, substance use) than their age-appropriate peers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Early enrollment",
"    </strong>",
"    &ndash; Parents also may advocate for early kindergarten enrollment (ie, at age four years) for their children who seem to have more advanced skills than their same-age peers. The ability of such children to successfully participate in kindergarten is comparable to children who entered kindergarten at five years of age if they have above-average intellectual abilities and well-developed socialization skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/81\">",
"     81",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    However, when controlling for effects of overall intelligence, children who were only slightly older than classmates at kindergarten entry showed modestly greater development across basic academic skills (eg, word decoding, number conceptualization, vocabulary, working memory) in the first few years of school, even though the groups did not differ on rudimentary skills demonstrated in kindergarten [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/70\">",
"     70",
"    </a>",
"    ]. Teacher ratings of academic mastery in second or third grade also favored children who were slightly older at kindergarten entry. Social functioning did not differ between these groups of children during the first few years after kindergarten.",
"    <br/>",
"    <br/>",
"    However, adverse effects of early enrollment may become evident as the children enter middle and junior high school, when physical maturation differences become more obvious. Although early enrollees typically continue to perform comparably in the academic arena, they may lag behind in the physical, and sometimes social, spheres and may be more likely to develop socioemotional difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/82-86\">",
"     82-86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     READINESS OF THE SCHOOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The readiness of the school refers to the educational system's ability to address the needs of young children, regardless of their cognitive abilities. This is a more recent concept than the readiness of the child.",
"   </p>",
"   <p>",
"    The school system should be prepared to educate kindergarten students who have a range of developmental abilities and skills. School characteristics (eg, teacher-student ratio, availability of multiple levels of instruction and remediation, and the number of children enrolled) can influence how well the various needs of individual students can be met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Educational Goals Panel (NEGP) proposed 10 characteristics of schools that are ready to support the learning and development of young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/41,87\">",
"     41,87",
"    </a>",
"    ]. Such schools:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smooth the transition between home and school (eg, by being sensitive to cultural differences and attempting to establish contact with families who are preparing to enroll their children).",
"     </li>",
"     <li>",
"      Strive for continuity between early care and education programs and between early education programs and elementary schools.",
"     </li>",
"     <li>",
"      Help children to learn and make sense of their complex and exciting world (eg, by using high-quality instructional aids with appropriate pacing and by demonstrating that learning occurs in the context of relationships).",
"     </li>",
"     <li>",
"      Are committed to the success of every child by being sensitive to individual needs, including poverty, race, and disability.",
"     </li>",
"     <li>",
"      Are committed to the success of every teacher and every adult who interacts with children during the school day (eg, by fostering continuing education and skill development). One such intervention might be providing additional training in the education of children who have emotional and behavioral difficulties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/2,63,88\">",
"       2,63,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Introduce or expand approaches that have been shown to raise achievement (eg, by encouraging parent involvement and monitoring teaching strategies).",
"     </li>",
"     <li>",
"      Alter practices and programs that do not benefit children.",
"     </li>",
"     <li>",
"      Serve children in communities, ensuring access to available services and supports.",
"     </li>",
"     <li>",
"      Take responsibility for results (eg, by using assessments to help plan for individual children and to measure accountability in the community).",
"     </li>",
"     <li>",
"      Are led by people who have a clear agenda and the authority to make and implement decisions in order to follow through on goals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above characteristics, schools must be willing to accommodate the special needs of children with chronic medical problems (eg, asthma, food allergies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/45\">",
"     45",
"    </a>",
"    ], developmental disabilities). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=see_link&amp;anchor=H9#H9\">",
"     \"Support services for the care of chronically ill children\", section on 'Education'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FAMILY AND COMMUNITY SUPPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the readiness of the school, family and community support for children's readiness is a relatively recent concept. The National Educational Goals Panel (NEGP) states, \"Families and communities shape the context in which children grow, framing children's most important early experiences and encounters with their environments\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/87\">",
"     87",
"    </a>",
"    ]. In accordance with this statement, the NEGP proposed that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All children should have access to high-quality and developmentally appropriate preschool programs.",
"     </li>",
"     <li>",
"      Children would receive the nutrition, physical activity, and health care they need to develop healthy minds and bodies and to maintain mental alertness.",
"     </li>",
"     <li>",
"      Every parent would be his or her child's first teacher and devote time each day to helping his or her child to learn; parents would be provided with the training and support needed to fulfill this role.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic health of infants and toddlers sets the stage for ability to function in school environments. As noted above, physical and mental difficulties can impede the acquisition of new skills and information, as well as the successful demonstration of knowledge. Thus, it is important to have interventions at the community level that are aimed at improving early health. Such interventions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Programs that provide monitoring, referral, education, and support",
"     </li>",
"     <li>",
"      Immunization initiatives",
"     </li>",
"     <li>",
"      Nutritional supplementation programs",
"     </li>",
"     <li>",
"      Programs that evaluate and treat mental health problems in parents and children",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Social",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of a child to participate in school activities also is related to his or her social environment. Providing social supports to families is another way to improve children's ability to participate in school. Examples of such interventions and their anticipated effects include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/3,15,89-92\">",
"     3,15,89-92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Finding approaches to alleviate poverty can improve nutrition and emotional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      behavioral problems",
"     </li>",
"     <li>",
"      Fostering involvement of both parents in divided families reduces the stress of single caregivers and also provides children with multiple models of adult behavior",
"     </li>",
"     <li>",
"      Providing parent training teaches caregivers how to model appropriate interaction and how to provide boundaries around their children wherein the children have the safety to develop increasing independence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Child care/Preschool",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the number of single-parent households or households in which both parents work increases, more children are cared for outside the home. In addition to providing a safe environment, child care programs should provide enriching and stimulating activities for the children they serve. To meet this goal, they must have appropriate staff-to-child ratios and well-educated and trained staff members. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Factors related to a child's ability to learn'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, the children should receive help in making the transition from child care centers or preschool to the more formal school setting of kindergarten. Communication between staff at the child care or preschool and kindergarten sites helps to facilitate this transition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/13,93\">",
"     13,93",
"    </a>",
"    ]. The staff at both sites should communicate with the parents to keep them apprised of the child's progress through the transition. Such communication can expedite the implementation of necessary support services if and when such services are necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Literacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community- or clinic-based literacy promotion programs support early school success by helping children to develop literacy skills. Early literacy is highly correlated with academic success; children who enter school with the least knowledge of beginning reading skills are at academic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Children whose parents read to them in the preschool years enter kindergarten with better skills than those whose parents do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/26,53,94,95\">",
"     26,53,94,95",
"    </a>",
"    ]. Exposure to printed material is beneficial, but so is exposure to games and songs that focus on phoneme sound comparisons and rhyming.",
"   </p>",
"   <p>",
"    The media, particularly television, has an ever-growing influence on the development of young children. Several educational programs foster literacy and psychosocial development (eg, \"Sesame Street\" and \"Mister Rogers' Neighborhood\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/16,96,97\">",
"     16,96,97",
"    </a>",
"    ]. However, excessive television viewing limits the time that children spend in other activities that promote learning (eg, reading, playing with peers, coloring, building with blocks, puzzles, etc). In addition, a large body of research demonstrates that watching violence, even in cartoon form, leads to increased aggressiveness and decreased fantasy play in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/98\">",
"     98",
"    </a>",
"    ]. The effects of witnessing television violence can be tempered through immediate discussion of the situation viewed and how it might have happened differently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38185/abstract/99\">",
"     99",
"    </a>",
"    ]. Television programming should be closely monitored by caregivers so as to take advantage of the benefits available and to ensure exposure to appropriate models of behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40343?source=see_link\">",
"     \"Television and media violence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROMOTION OF SCHOOL READINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, school readiness is a multifaceted concept. All components of optimal preparation (of the child, school, and community) as outlined by the National Educational Goals Panel (NEGP) have not yet been implemented. Nonetheless, there are some steps that parents can take toward making sure that all children enter school ready to learn. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ensuring that their child has adequate nutrition and maintains regular sleep habits",
"     </li>",
"     <li>",
"      Expanding their preschool-age child's cognitive, fine motor, language, and psychosocial skills through mindful participation in routine activities of living, as well as structured",
"      <span class=\"nowrap\">",
"       teaching/learning",
"      </span>",
"      projects (",
"      <a class=\"graphic graphic_table graphicRef70285 graphicRef74888 graphicRef54909 \" href=\"mobipreview.htm?27/36/28238\">",
"       table 1A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maintaining communication with their child's teachers and personnel in local school districts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preparation of children for school includes minimization of risk factors for school problems or failure (eg, poverty, low birth weight, developmental delay). This includes early identification of problems through screening programs, and early intervention when such problems are identified. To this end, pediatric care providers are well advised to consider:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Providing regular health maintenance, including developmental screening for their patients (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=see_link\">",
"       \"Developmental and behavioral screening tests in primary care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"       \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Referring their patients who are at risk for developmental problems to early intervention programs as soon as such problems are identified",
"     </li>",
"     <li>",
"      Taking advantage of Head Start programs in their communities",
"     </li>",
"     <li>",
"      Regularly screening their patients for hearing and vision problems",
"     </li>",
"     <li>",
"      Promoting good nutrition and regular physical activity as part of basic health",
"     </li>",
"     <li>",
"      Screening their patients for medical or social conditions that affect school performance (eg, lead poisoning, poor nutrition, sleep problems, poverty, domestic violence, maternal depression)",
"     </li>",
"     <li>",
"      Optimizing therapy for chronic medical problems so their patients do not miss school for acute exacerbations; communicating with the schools regarding the medical needs of their patients",
"     </li>",
"     <li>",
"      Keeping their patients' immunizations current",
"     </li>",
"     <li>",
"      Encouraging parents to read to their children and support home-based early education efforts (",
"      <a class=\"graphic graphic_table graphicRef70285 graphicRef74888 graphicRef54909 \" href=\"mobipreview.htm?27/36/28238\">",
"       table 1A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Communicating with parents, day care providers, and teachers, particularly if the child is at risk for school problems",
"     </li>",
"     <li>",
"      Advocating for community programs that support children's success in school, which have been shown to have positive cost-benefit outcomes in addition to promoting academic skill attainment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1032401829\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources that may be helpful to families include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Learning to Get Along series of books by Cheri J. Meiners &ndash; The books cover such topics as working through conflicts, respecting others&rsquo; property, valuing individual differences, sharing and taking turns, persevering when new activities are difficult, and other social issues. They generally are appropriate for preschool and early elementary school-aged children.",
"     </li>",
"     <li>",
"      Parenting the Strong-willed Child: The Clinically Proven Five-Week Program for Parents of Two- to Six-Year-Olds by Rex Forehand and Nicholas Long (2010) &ndash; This book provides a good introduction to the function of behaviors and the factors that contribute to them as well as strategies and skills needed to manage behavior problems. It is geared toward preschool and elementary school-aged children.",
"     </li>",
"     <li>",
"      The Reader Rabbit program &ndash; This is an excellent (and fun) academic instruction program that provides learning activities for reading and math. It is aimed at early and middle childhood ages. The Reader Rabbit program is available through",
"      <a class=\"external\" href=\"file://www.reader-rabbit.com/\">",
"       www.reader-rabbit.com",
"      </a>",
"      , local stores, and online distributors. It may be used at a local library if a home computer is not available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The concept of school readiness encompasses preparing children, schools, and communities to maximize the educational experience for all children, regardless of developmental ability or health condition. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Components of readiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are five domains of school readiness for the child: physical well-being and motor development; social and emotional development; the child&rsquo;s approach to learning; language development; and cognition and general knowledge. Children&rsquo;s mastery of specific skills before kindergarten entry varies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Readiness of the child'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For typically developing children, neither delayed nor early entrance into kindergarten has been shown to yield substantial differences in academic skill development after the first few years of school. (See",
"      <a class=\"local\" href=\"#H558613169\">",
"       'Delayed or early enrollment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The readiness of the school refers to the educational system's ability to address the needs of the young children, regardless of the child&rsquo;s cognitive abilities. The school system should be prepared to educate kindergarten students who have a range of developmental abilities and skills. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Readiness of the school'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Community and family supports for school readiness include high-quality preschool programs; programs to optimize the child&rsquo;s nutrition, physical activity, and health (eg, supplemental nutrition programs, immunization initiatives); and programs that help parents to be more effective in their role as their child&rsquo;s first teacher (",
"      <a class=\"graphic graphic_table graphicRef70285 graphicRef74888 graphicRef54909 \" href=\"mobipreview.htm?27/36/28238\">",
"       table 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Family and community supports'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/1\">",
"      Fowler MG, Cross AW. Preschool risk factors as predictors of early school performance. J Dev Behav Pediatr 1986; 7:237.",
"     </a>",
"    </li>",
"    <li>",
"     Raver CC, Knitzer J. Ready to Enter: What Research Tells Policymakers about Strategies to Promote Social and Emotional School Readiness Among Three- and Four-Year-Old Children, National Center for Children in Poverty, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/3\">",
"      Reynolds AJ, Temple JA, Robertson DL, Mann EA. Long-term effects of an early childhood intervention on educational achievement and juvenile arrest: A 15-year follow-up of low-income children in public schools. JAMA 2001; 285:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/4\">",
"      Lewit EM, Baker LS. School readiness. Future Child 1995; 5:128.",
"     </a>",
"    </li>",
"    <li>",
"     Educating America: State strategies for achieving the national goals. Report of the Task Force on Education, Feinstein G (Ed), National Governors Association, Washington DC 1990.",
"    </li>",
"    <li>",
"     Goals 2000: Educate America Act (PL 103-227), 1994. www.ed.gov/legislation/GOALS2000/TheAct (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     www.ed.gov/legislation/GOALS2000/TheAct. The National Education Goals Report: Building a Nation of Learners, Government Printing Office, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/8\">",
"      Crnic K, Lamberty G. Reconsidering school readiness: Conceptual and applied perspectives. Early Educ Dev 1994; 5:91.",
"     </a>",
"    </li>",
"    <li>",
"     Boyer EL. Ready to Learn: A Mandate for the Nation, Carnegie Foundation for the Advancement of Teaching, Princeton, NJ 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/10\">",
"      National Association for the Education of Young Children. NAEYC position statement on school readiness. Young Child 1990; 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/11\">",
"      The inappropriate use of school \"readiness\" tests. American Academy of Pediatrics Committee on School Health and Committee on Early Childhood, Adoption and Dependent Care. Pediatrics 1995; 95:437.",
"     </a>",
"    </li>",
"    <li>",
"     Ratliff-Schaub. School Readiness. In: American Academy of Pediatrics Textbook of Pediatric Care, McInerny TK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.1140.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/13\">",
"      Casey PH, Evans LD. School readiness: an overview for pediatricians. Pediatr Rev 1993; 14:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/14\">",
"      Byrd RS, Weitzman ML. Predictors of early grade retention among children in the United States. Pediatrics 1994; 93:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/15\">",
"      Greenberg MT, Domitrovich C, Bumgarger B. The prevention of mental disorders in school-aged children: Current state of the field. Prev Treatment 2001; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     School Readiness: Helping Communities Get Children Ready for School and Schools Ready for Children, Emig C, Moore A, Scarup, HJ (Eds), Child Trends 2001. www.childtrends.org/files/schoolreadiness.pdf (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/17\">",
"      Ackerman BP, Izard CE, Schoff K, et al. Contextual risk, caregiver emotionality, and the problem behaviors of six- and seven-year-old children from economically disadvantaged families. Child Dev 1999; 70:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/18\">",
"      Burchinal MR, Roberts JE, Hooper S, Zeisel SA. Cumulative risk and early cognitive development: a comparison of statistical risk models. Dev Psychol 2000; 36:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/19\">",
"      Chronicity of maternal depressive symptoms, maternal sensitivity, and child functioning at 36 months. NICHD Early Child Care Research Network. Dev Psychol 1999; 35:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/20\">",
"      Wyman PA, Cowen EL, Work WC, et al. Caregiving and developmental factors differentiating young at-risk urban children showing resilient versus stress-affected outcomes: a replication and extension. Child Dev 1999; 70:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/21\">",
"      Campbell FA, Ramey CT. Effects of early intervention on intellectual and academic achievement: a follow-up study of children from low-income families. Child Dev 1994; 65:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/22\">",
"      Boat BW, Campbell FA, Ramey CT. Preventive education and birth order as co-determinants of IQ in disadvantaged 5-year-olds. Child Care Health Dev 1986; 12:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/23\">",
"      Ramey CT, Campbell FA. Preventive education for high-risk children: cognitive consequences of the Carolina Abecedarian Project. Am J Ment Defic 1984; 88:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/24\">",
"      Ramey CT, Campbell FA. Early childhood education for psychosocially disadvantaged children: effects on psychological processes. Am J Ment Defic 1979; 83:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/25\">",
"      Ramey CT, Ramey SL. Prevention of intellectual disabilities: early interventions to improve cognitive development. Prev Med 1998; 27:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/26\">",
"      S&eacute;n&eacute;chal M, LeFevre JA. Parental involvement in the development of children's reading skill: a five-year longitudinal study. Child Dev 2002; 73:445.",
"     </a>",
"    </li>",
"    <li>",
"     McCormick CE, Mason JM.. Intervention procedures for increasing preschool children's interest in and knowledge about reading. In: Emergent Literacy: Writing and Reading, Teale W, Sulzby E (Eds), Ablex Publishing Corp, Norwood, NJ 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/28\">",
"      Zill N, Collins M, West J, et al. Approaching kindergarten: A look at preschoolers in the United States. Young Child 1995; 51:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/29\">",
"      Taylor AR. Social competence and early school transition: Risk and protective factors for African-American children. Educ Urban Soc 1991; 24:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/30\">",
"      Lee VE, Brooks-Gunn J, Schnur E, Liaw FR. Are Head Start effects sustained? A longitudinal follow-up comparison of disadvantaged children attending Head Start, no preschool, and other preschool programs. Child Dev 1990; 61:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/31\">",
"      Barnett WS. Long-term cognitive and academic effects of early childhood education on children in poverty. Prev Med 1998; 27:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/32\">",
"      Campbell FA, Pungello EP, Miller-Johnson S, et al. The development of cognitive and academic abilities: growth curves from an early childhood educational experiment. Dev Psychol 2001; 37:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/33\">",
"      Anderson LM, Shinn C, Fullilove MT, et al. The effectiveness of early childhood development programs. A systematic review. Am J Prev Med 2003; 24:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/34\">",
"      Parker FL, Boak AY, Griffin KW, et al. Parent-child relationship, home learning environment, and school readiness. School Psychol Rev 1999; 28:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/35\">",
"      Reynolds AJ. Resilience among black urban youth. Prevalence, intervention effects, and mechanisms of influence. Am J Orthopsychiatry 1998; 68:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/36\">",
"      Zoritch B, Roberts I, Oakley A. Day care for pre-school children. Cochrane Database Syst Rev 2000; :CD000564.",
"     </a>",
"    </li>",
"    <li>",
"     Karoly LA, Bigelow JH. The Economics of Investing in Universal Preschool Education in California, Rand Corporation, Santa Monica 2005.",
"    </li>",
"    <li>",
"     Rolnick F, Grunewald R. Technical report: Early childhood development: Economic development with a high public return. Minneapolis, MN: Federal Reserve Bank of Minneapolis 2003. Available at: www.minneapolisfed.org/research/pub_display.cfm?id=3832 (Accessed on September 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/39\">",
"      Heckman JJ. Skill formation and the economics of investing in disadvantaged children. Science 2006; 312:1900.",
"     </a>",
"    </li>",
"    <li>",
"     Reconsidering Children's Early Development and Learning: Toward Common Views and Vocabulary. National Education Goals Panel, Goal 1 Technical Planning Group Report 95/03, Kagan SL, Moore E, Bredekamp S (Eds), Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/41\">",
"      High PC, American Academy of Pediatrics Committee on Early Childhood, Adoption, and Dependent Care and Council on School Health. School readiness. Pediatrics 2008; 121:e1008.",
"     </a>",
"    </li>",
"    <li>",
"     Zill N, West J. US Department of Education, National Center for Education Statistics. Entering Kindergarten: A Portrait of American Children When They Begin School: Findings from The Condition of Education 2000. NCES 2001-035, Washington, DC: US Government Printing Office, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/43\">",
"      Msall ME, Buck GM, Rogers BT, Catanzaro NL. Kindergarten readiness after extreme prematurity. Am J Dis Child 1992; 146:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/44\">",
"      Case-Smith J. Fine motor outcomes in preschool children who receive occupational therapy services. Am J Occup Ther 1996; 50:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/45\">",
"      Rhim GS, McMorris MS. School readiness for children with food allergies. Ann Allergy Asthma Immunol 2001; 86:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/46\">",
"      Ravid S, Afek I, Suraiya S, et al. Kindergarten children's failure to qualify for first grade could result from sleep disturbances. J Child Neurol 2009; 24:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/47\">",
"      Bierman KL, Domitrovich CE, Nix RL, et al. Promoting academic and social-emotional school readiness: the head start REDI program. Child Dev 2008; 79:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/48\">",
"      Raver CC, Jones SM, Li-Grining C, et al. CSRP's Impact on low-income preschoolers' preacademic skills: self-regulation as a mediating mechanism. Child Dev 2011; 82:362.",
"     </a>",
"    </li>",
"    <li>",
"     McClellan DE, Katz LG. Young children's social development: A checklist (ERIC Identifier: ED356100). Eric Digest, ERIC Clearinghouse on Elementary and Early Childhood Education, Urbana, IL, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/50\">",
"      Blair C. School readiness. Integrating cognition and emotion in a neurobiological conceptualization of children's functioning at school entry. Am Psychol 2002; 57:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/51\">",
"      Serna L, Nielson E, Lambros K, et al. Primary prevention with children at risk for emotional or behavioral disorders: Data on a universal intervention for Head Start classrooms. Behav Disord 2000; 26:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/52\">",
"      Zhai F, Brooks-Gunn J, Waldfogel J. Head Start and urban children's school readiness: a birth cohort study in 18 cities. Dev Psychol 2011; 47:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/53\">",
"      Mendelsohn AL, Huberman HS, Berkule SB, et al. Primary care strategies for promoting parent-child interactions and school readiness in at-risk families: the Bellevue Project for Early Language, Literacy, and Education Success. Arch Pediatr Adolesc Med 2011; 165:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/54\">",
"      Agostin TM, Bain S. Retention in kindergarten. Psychol Sch 1997; 34:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/55\">",
"      Ladd GW, Burgess KB. Charting the relationship trajectories of aggressive, withdrawn, and aggressive/withdrawn children during early grade school. Child Dev 1999; 70:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/56\">",
"      Ladd GW, Kochenderfer BJ, Coleman CC. Classroom peer acceptance, friendship, and victimization: distinct relational systems that contribute uniquely to children's school adjustment? Child Dev 1997; 68:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/57\">",
"      McClelland MM, Morrison FJ, Holmes DS. Children at risk for early academic problems: The role of learning-related social skills. Early Childhood Research Quarterly 2000; 15:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/58\">",
"      Ladd GW, Birch SH, Buhs ES. Children's social and scholastic lives in kindergarten: related spheres of influence? Child Dev 1999; 70:1373.",
"     </a>",
"    </li>",
"    <li>",
"     Denton K. Germino-Hausken E. America's Kindergargeners, NCES 2000-070. National Center for Education Statistics, United States Department of Education. Washington, DC, 2000. nces.ed.gov/pubs2000/2000070.pdf (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/60\">",
"      Kupersmidt JB, Bryant D, Willoughby M. Prevalence of aggressive behaviors among preschools in Head Start and community child care programs. Behav Disord 2000; 26:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/61\">",
"      Willoughby M, Kupersmidt J, Bryant D. Overt and covert dimensions of antisocial behavior in early childhood. J Abnorm Child Psychol 2001; 29:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/62\">",
"      Lopez ML, Tarullo LB, Forness SR, et al. Early identification and intervention: Head Start's response to mental health challenges. Early Educ Dev 2000; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/63\">",
"      Arnold DH, McWilliams L, Arnold EH. Teacher discipline and child misbehavior in day care: untangling causality with correlational data. Dev Psychol 1998; 34:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/64\">",
"      Justice LM, Bowles RP, Pence Turnbull KL, Skibbe LE. School readiness among children with varying histories of language difficulties. Dev Psychol 2009; 45:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/65\">",
"      High PC, LaGasse L, Becker S, et al. Literacy promotion in primary care pediatrics: can we make a difference? Pediatrics 2000; 105:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/66\">",
"      Mendelsohn AL, Mogilner LN, Dreyer BP, et al. The impact of a clinic-based literacy intervention on language development in inner-city preschool children. Pediatrics 2001; 107:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/67\">",
"      Theriot JA, Franco SM, Sisson BA, et al. The impact of early literacy guidance on language skills of 3-year-olds. Clin Pediatr (Phila) 2003; 42:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/68\">",
"      Sharif I, Rieber S, Ozuah PO, Reiber S. Exposure to Reach Out and Read and vocabulary outcomes in inner city preschoolers. J Natl Med Assoc 2002; 94:171.",
"     </a>",
"    </li>",
"    <li>",
"     West J, Hausken EG, Collins M. Readiness for kindergarten: parent and teacher beliefs. Statistics in Brief (NCES 93257), U.S. Department of Education, National Center for Education Statistics, Washington, DC, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/70\">",
"      NICHD Early Child Care Research Network. Age of Entry to Kindergarten and Children's Academic Achievement and Socioemotional Development. Early Educ Dev 2007; 18:337.",
"     </a>",
"    </li>",
"    <li>",
"     Shepard LA. A review of research on kindergarten retention. In: Flunking Grades: Research and Policies on Retention, Shepard LA, Smith ML (Eds), Falmer Press, London 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/72\">",
"      Cameron MB, Wilson BJ. The effects of chronological age, gender, and delay of entry on academic achievement and retention: Implications for academic redshirting. Psychol Sch 1990; 27:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/73\">",
"      Jones MM, Mandeville GK. The effect of age at school entry on reading achievement scores among South Carolina students. Remedial and Special Education 1990; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/74\">",
"      Kundert DK, May DC, Brent D. A comparison of students who delay kindergarten entry and those who are retained in grades K-5. Psychol Sch 1995; 32:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/75\">",
"      May D, Kundert D, Brent D. Does delayed school entry reduce later grade retention and use of special education services. Remedial and Special Education 1995; 16:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/76\">",
"      Morrison FJ, Griffith EM, Alberts DM. Nature-nurture in the classroom: entrance age, school readiness, and learning in children. Dev Psychol 1997; 33:254.",
"     </a>",
"    </li>",
"    <li>",
"     Grisson J, Shepard LA. Repeating and dropping out of school. In: Flunking Grades: Research and Policies on Retention, Shepard LA, Smith ML (Eds), Falmer Press, London 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/78\">",
"      Shepard L, Smith M. Synthesis of research on grade retention. Educ Leadersh 1990; May:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/79\">",
"      Byrd RS, Weitzman M, Auinger P. Increased behavior problems associated with delayed school entry and delayed school progress. Pediatrics 1997; 100:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/80\">",
"      Byrd RS, Weitzman M, Doniger AS. Increased drug use among old-for-grade adolescents. Arch Pediatr Adolesc Med 1996; 150:470.",
"     </a>",
"    </li>",
"    <li>",
"     Laidig P. School Entry Decisions: A Guide for Parents. file://www.schoolhousedoor.com/media/parents/art_entrydecisions.txt (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/82\">",
"      Beer J. Depression, general anxiety, test anxiety, and rigidity of gifted junior high and high school children. Psychol Rep 1991; 69:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/83\">",
"      Laitinen-Krispijn S, Van der Ende J, Hazebroek-Kampschreur AA, Verhulst FC. Pubertal maturation and the development of behavioural and emotional problems in early adolescence. Acta Psychiatr Scand 1999; 99:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/84\">",
"      Williams JM, Dunlop LC. Pubertal timing and self-reported delinquency among male adolescents. J Adolesc 1999; 22:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/85\">",
"      Winner E. The origins and ends of giftedness. Am Psychol 2000; 55:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/86\">",
"      Goodman R, Gledhill J, Ford T. Child psychiatric disorder and relative age within school year: cross sectional survey of large population sample. BMJ 2003; 327:472.",
"     </a>",
"    </li>",
"    <li>",
"     Reconsidering Children's Early Development and Learning: Toward Common Views and Vocabulary. National Education Goals Panel, Goal 1 Technical Planning Group Report 95/03, Kagan SL, Moore E, Bredekamp S (Eds), Washington, 1995.",
"    </li>",
"    <li>",
"     Peth-Pierce R. A Good Beginning: Sending America's Children to School with the Social and Emotional Competence They Need to Succeed. Monograph prepared by FAN: The Child Mental Health Foundations and Agencies Network.",
"    </li>",
"    <li>",
"     Patterson GR, Capaldi D, Bank L. An early starter model of predicting delinquency. In: The Development and Treatment of Childhood Aggression, Pepler DJ, Rubin KH (Eds), Sage, Newbury Park, CA 1991.",
"    </li>",
"    <li>",
"     Ramey CT, Ramey SL. Beginning school for children at risk. In: The Transition to Kindergarten, Pianta RC, Cox MJ (Eds), Paul H. Brookes, Baltimore 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/91\">",
"      Reid JB. Prevention of conduct disorder before and after school entry: Relating interventions to developmental findings. Dev Psychopathol 1993; 5:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/92\">",
"      Reid MJ, Webster-Stratton C, Beauchaine TP. Parent training in head start: a comparison of program response among African American, Asian American, Caucasian, and Hispanic mothers. Prev Sci 2001; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/93\">",
"      Dworkin PH. Ready to learn: a mandate for pediatrics. J Dev Behav Pediatr 1993; 14:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/94\">",
"      Bus AG, van Ijzendoorn MH, Pelligrini AD. Joint book reading makes for success in learning to read: A meta-analysis on intergenerational transmission of literacy. Rev Educ Res 1995; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/95\">",
"      Atkinson PM, Parks DK, Cooley SM, Sarkis SL. Reach Out and Read: a pediatric clinic-based approach to early literacy promotion. J Pediatr Health Care 2002; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     Huston AC, Wright JC. Mass media and children's development. In: Handbook of Child Psychology, Sigel IE, Benninger KA (Eds), John Wiley &amp; Sons, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/97\">",
"      Wright JC, Huston AC, Murphy KC, et al. The relations of early television viewing to school readiness and vocabulary of children from low-income families: the early window project. Child Dev 2001; 72:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/98\">",
"      Hughes JN, Hasbrouck JE. Television violence: Implications for violence prevention. School Psychol Rev 1996; 25:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38185/abstract/99\">",
"      Huesmann LR, Eron LD, Klein R, et al. Mitigating the imitation of aggressive behaviors by changing children's attitudes about media violence. J Pers Soc Psychol 1983; 44:899.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 592 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38185=[""].join("\n");
var outline_f37_18_38185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS RELATED TO A CHILD'S ABILITY TO LEARN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPONENTS OF READINESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      READINESS OF THE CHILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical well-being",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28744564\">",
"      Social and emotional development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Approach to learning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Language development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General knowledge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronologic age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558613169\">",
"      - Delayed or early enrollment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      READINESS OF THE SCHOOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FAMILY AND COMMUNITY SUPPORTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Social",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Child care/Preschool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Literacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROMOTION OF SCHOOL READINESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1032401829\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/62/32748\" title=\"table 1A\">",
"      Promotion of general knowledge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/26/8621\" title=\"table 1B\">",
"      Promotion of language literacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/17/8476\" title=\"table 1C\">",
"      Promotion of psychosocial skills",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10599?source=related_link\">",
"      Emergent literacy including language development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=related_link\">",
"      Food allergy in schools and camps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32679?source=related_link\">",
"      Support services for the care of chronically ill children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40343?source=related_link\">",
"      Television and media violence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_18_38186="Geriatric health maintenance";
var content_f37_18_38186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Geriatric health maintenance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38186/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38186/contributors\">",
"     Mitchell T Heflin, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38186/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38186/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/18/38186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/18/38186/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/18/38186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The profile of aging in the United States (US) has changed dramatically over the last century. The average life expectancy at birth has increased from 47 years in 1900 to over 78 years in 2008. By 2030, the percentage of the population over 65 years of age will exceed 20 percent, or over 70 million people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitions of health and well-being in late life have changed with the increase in life expectancy. Heart disease, cancer, and stroke have become the leading \"killers\" among older adults, while deaths due to infection have decreased. Adults surviving into late life suffer from high rates of chronic illness; 80 percent have at least one and 50 percent have at least two chronic conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/1\">",
"     1",
"    </a>",
"    ]. There is a strong association between the presence of geriatric syndromes (cognitive impairment, falls, incontinence, vision or hearing impairment, low body mass index, dizziness) and dependency in activities of daily living (relative risk 2.1 for one condition; 6.6 for three or more conditions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decline in function and loss of independence are NOT an inevitable consequence of aging. Given the high prevalence and impact of chronic health problems among older patients, evidence-based interventions to address these problems become increasingly important to maximize both the quantity and quality of life for older adults.",
"   </p>",
"   <p>",
"    The Assessing Care of Vulnerable Elders (ACOVE-3) project identifies quality indicators in the care of older adults, including recommendations for routine health maintenance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinician experts serving as authors for this project have critically evaluated the evidence supporting these quality indicators, and their review, in conjunction with other sources, is used in the development of this discussion.",
"   </p>",
"   <p>",
"    This topic offers a brief discussion of office-based assessments to identify and address common problems that are amenable to prevention or amelioration in older adults. An overview of preventive medicine for the general population is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104693352\">",
"    <span class=\"h1\">",
"     GOALS OF CARE FOR OLDER ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older individuals differ greatly in their physiologic and functional status. This wide heterogeneity in health states among older adults means that treatment decisions, both preventive and therapeutic, should be considered based on individual needs. Age alone should not be the sole determinant for many interventions, and all treatments should aim to preserve function and maximize quality of life. Studies suggest that many older patients in the US, and women in particular, both receive screening tests that are inappropriate for their age or health status and do not receive other screening tests and preventive interventions (eg, immunizations and counseling) that are recommended for health maintenance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A proposed framework for primary care for older individuals that defines short-term, mid-range, and long-term goals may help providers more appropriately and effectively prioritize issues in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/6\">",
"     6",
"    </a>",
"    ]. Short-term issues focus on immediate needs to maintain or restore current health status and may be the sole focus for patients at the end of life. Such issues may relate to symptom management, care coordination, personal safety, and living situation. Mid-range issues, addressing needs over the subsequent one to five years, involve preventive care, disease management, psychological issues, and coping strategies. Long-term issues, relating to plans to be implemented at the time of eventual decline, are important to consider for older adults who are currently healthy and high-functioning. Approximations of life expectancy based on health and function can help providers, patients, and caregivers in prioritizing issues and making decisions. Evidence-based tools available online at",
"    <a class=\"external\" href=\"file://www.eprognosis.org/\">",
"     www.eprognosis.org",
"    </a>",
"    can help generate estimates of survival for older adults with different conditions and in different settings.",
"   </p>",
"   <p>",
"    While this topic is organized around a more traditional preventive care model, providers are encouraged to consider the individual patients&rsquo; health status, preferences, and priorities in management of the issues discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF PREVENTIVE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologists have traditionally categorized strategies for disease prevention and health promotion into three levels: primary, secondary, and tertiary. This is the terminology that will be used in this discussion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prevention aims to avert the development of disease. Immunizations, life style modifications (smoking cessation, promoting physical activity), and chemoprophylaxis (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for primary prevention of heart disease) fall under the category of primary prevention.",
"     </li>",
"     <li>",
"      Secondary prevention focuses on early detection and treatment of asymptomatic disease. Screening for cancer, hearing or vision impairment, osteoporosis, hypertension, and abdominal aortic aneurysm (AAA) are examples of secondary prevention.",
"     </li>",
"     <li>",
"      Tertiary prevention identifies established conditions to prevent further morbidity or functional decline. Identification of cognitive problems, disorders of gait and balance, malnutrition, and urinary incontinence are examples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that there is discrepancy in terminology as commonly used in the epidemiological and clinical literature. Thus, the term \"secondary prevention\" as defined here refers to early detection of asymptomatic disease, generally by screening, while the term \"secondary prevention\" as used by cardiologists and others refers to prevention of further events in patients with known established disease. Thus, targeting lower cholesterol levels or using beta blockers in patients with known coronary disease is referred to by cardiologists as \"secondary prevention\" but would be identified as tertiary prevention in the nomenclature discussed here.",
"   </p>",
"   <p>",
"    Similarly, screening for dyslipidemia is referred to here as \"secondary prevention\" but is often considered primary prevention by cardiologists and others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise benefits people of all ages and may decrease all cause morbidity and increase lifespan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All older adults, including the very old, those with multiple morbidities, or those who are in chronic care facilities, can benefit from physical activity. Participation in any amount of physical activity will result in some health benefit. A description of the benefits of exercise and a full discussion of exercise recommendations for older adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9161?source=see_link\">",
"     \"Physical activity and exercise in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Heart Association (AHA) and the American College of Sport Medicine (ACSM) provide recommendations for adults over age 65 years for various types of activity and guides for implementing such programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/9\">",
"     9",
"    </a>",
"    ]. Specific exercises fall into four categories: aerobic, muscle strengthening, flexibility, and balance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For aerobic activity, guidelines suggest a minimum of 30 minutes of moderate-intensity exercise on five days each week, or a minimum of 20 minutes of vigorous-intensity activity on three days each week, or some combination of the two [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/9\">",
"       9",
"      </a>",
"      ]. Definitions for moderate and vigorous activity depend on the person's baseline conditioning.",
"     </li>",
"     <li>",
"      Exercises to maintain and increase muscle strength include weight training, weight bearing calisthenics, or resistance training.",
"     </li>",
"     <li>",
"      Evidence supporting flexibility activities is less rigorous, but most experts recommend 10 minutes of some static stretching of major muscle groups on days when aerobic or muscle strengthening exercise is performed, to maintain range of motion.",
"     </li>",
"     <li>",
"      Balance training exercises are recommended to improve stability and prevent falls and injuries related to falls. Static balance training involves learning to recover balance on a tilting balance platform. Dynamic balance training, such as Tai Chi, may be more accessible outside of a formal supervised setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/10-12\">",
"       10-12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AHA/ACSM",
"    </span>",
"    guidelines emphasize a graduated or stepwise introduction of physical activity to improve safety and adherence. An individualized \"activity plan\" should recommend levels of physical activity and define how the individual will meet them. Developing an activity plan, particularly for older adults with chronic conditions, may warrant input from physical",
"    <span class=\"nowrap\">",
"     therapists/exercise",
"    </span>",
"    physiologists or referral to specialty programs (eg, cardiac or pulmonary rehabilitation). Routine electrocardiogram (EKG) or cardiac exercise testing are not indicated for asymptomatic patients who are preparing to undergo an exercise program. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link&amp;anchor=H5#H5\">",
"     \"Screening for coronary heart disease\", section on 'Exercise ECG testing in asymptomatic individuals'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9161?source=see_link&amp;anchor=H4894206#H4894206\">",
"     \"Physical activity and exercise in older adults\", section on 'Initiating exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tobacco use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of smoking and tobacco use are lower for adults over age 65 than for younger individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/13\">",
"     13",
"    </a>",
"    ]. Nonetheless, the older generation has a long history of high rates of smoking and excess smoking-related mortality from lung cancer, cardiovascular disease, and chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-quality evidence demonstrates that smoking cessation significantly reduces the risk for coronary heart disease, various cancers, and chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/15\">",
"     15",
"    </a>",
"    ]. One study addressed smoking cessation in older community-dwelling adults and found that, within five years of stopping smoking, the relative risk for all cause mortality fell below that for current smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACOVE authors identified several smoking cessation techniques that were effective in general clinical practice, including physician recommendation, formal counseling, and pharmacotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/3\">",
"     3",
"    </a>",
"    ]. Ongoing regular counseling for smoking cessation for all patients who use tobacco products is recommended by the United States Preventive Services Task Force (USPSTF). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nicotine replacement, although not specifically studied in older individuals, has been shown to be effective as an adjunct for selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/17\">",
"     17",
"    </a>",
"    ]. Other options, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    , may also be reasonable choices for older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 percent of adults over age 65 years experience health problems related to the complications of alcohol consumption in combination with medication or chronic conditions. Two to 4 percent meet criteria for alcoholism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/19\">",
"     19",
"    </a>",
"    ]. Alcohol use in older adults may negatively impact function and cognition, as well as general health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for alcohol abuse among older adults include bereavement, depression, anxiety, pain, disability, and a prior history of alcohol use. A variety of screening tools are effective for identifying alcohol misuse in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/3\">",
"     3",
"    </a>",
"    ]. The American Geriatrics Society guidelines suggest specific questioning regarding the frequency and quantity of alcohol use followed by asking the CAGE questions (Cut down, Annoyed, Guilty, Eye-opener) to identify patients with alcohol related problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link&amp;anchor=H1272522#H1272522\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'CAGE questions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The National Institute on Alcohol Abuse and Alcoholism (NIAAA) has developed an excellent clinician tool for helping patients who consume alcohol to excess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/20\">",
"     20",
"    </a>",
"    ]. Physician recommendations and advice may be as effective as more detailed behavioral counseling programs at reducing alcohol use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aspirin for primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;USPSTF guidelines \"strongly recommend\" that clinicians discuss",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    chemoprevention in adults who are at increased risk for cardiovascular disease (five-year risk of &ge;3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/17\">",
"     17",
"    </a>",
"    ]. Results of the Women's Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/21\">",
"     21",
"    </a>",
"    ] and a systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/22\">",
"     22",
"    </a>",
"    ] suggest that the benefits and risks of aspirin for coronary heart disease and stroke may differ in men and women. Aspirin appears to provide men with protection from first myocardial infarction, and women from first ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks of gastrointestinal bleeding with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in older adults are well documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/23\">",
"     23",
"    </a>",
"    ]. A decision analysis indicated that risks of gastrointestinal bleeding may offset the benefit of preventing a first myocardial infarction or stroke among some older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/24\">",
"     24",
"    </a>",
"    ]. Individual risks for bleeding, stroke, and coronary events should be reviewed with older patients in the process of shared decision making regarding aspirin use as primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Gastroenterology/American",
"    </span>",
"    Heart Association, however, suggest using a PPI for all patients over 60 years of age who are maintained on chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Prevention strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of recommended immunizations for adults from the United States Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) is shown in a table (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tetanus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical tetanus, though rare in the United States, occurs predominantly in unvaccinated or underimmunized older adults. Patients older than 60 years account for approximately 60 percent of all cases of tetanus in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF recommends booster doses of adult-type tetanus and diphtheria toxoid every 10 years, although longer intervals are probably adequate for those vaccinated in childhood or young adulthood. Studies have demonstrated the efficacy and cost-effectiveness of a single booster in producing sustained immunity to both tetanus and diphtheria among older patients (aged 50 to 70) who had received a primary booster series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The Advisory Committee on Immunization Practices (ACIP) still recommends a booster every 10 years, while the American College of Physicians (ACP) and the ACOVE authors support a single Td booster in late life (age &gt;50 years) in patients who have completed the primary series and have not had a booster within the last 10 years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In fall 2010, the ACIP voted to recommend that a single dose of Tdap vaccine may be given in place of Td for adults &ge;65 years who have not received Tdap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This is important for adults &ge;65 who have close contact with infants aged younger than one year (such as grandparents, child care providers, and health care providers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/32\">",
"     32",
"    </a>",
"    ]. Tdap should be administered regardless of the interval since the last dose of Td. This represents a change from previous ACIP guidelines, which recommended that Tdap be given a minimum of two years after the last dose of Td in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 90 percent of influenza-related deaths occur among people &ge;60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/33\">",
"     33",
"    </a>",
"    ]. Older adults also experience significantly increased morbidity from the disease.",
"   </p>",
"   <p>",
"    Meta-analyses indicate that influenza vaccination may reduce the incidence of influenza, influenza-like illness, hospitalization rates for pneumonia and influenza, and deaths after hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Although one epidemiological study did not show mortality benefit for influenza vaccination in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/36\">",
"     36",
"    </a>",
"    ], a more recent observational study, involving over 700,000 older person seasons, found that influenza vaccination was associated with reduced risk for hospitalization (OR 0.73; 95% CI 0.68-0.77) and an almost 50 percent reduction in mortality (OR 0.52, 0.50-0.55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link&amp;anchor=H14#H14\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Elderly patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Annual influenza immunization for all adults is recommended by the Centers for Disease Control (CDC) as of 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/38\">",
"     38",
"    </a>",
"    ]. The live attenuated intranasal preparation (Flumist) is not approved for use in adults over age 50. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In December 2009, the US Food and Drug Administration approved a high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    for individuals &ge;65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/39\">",
"     39",
"    </a>",
"    ]. The approval was based on data showing increased immunogenicity of the high-dose vaccine in older adults. However, the Advisory Committee on Immunization Practices has not stated a preference for this vaccine over the standard dose vaccine in older adults since there are no data demonstrating greater protection against influenza illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal disease is a significant cause of morbidity and mortality in older adults. A 23-valent polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) are available, but only PPSV23 is recommended for healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/40\">",
"     40",
"    </a>",
"    ]. All adults 65 years of age and older should receive a dose of PPSV23 even if they were vaccinated when they were younger than 65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a minimum interval of five years between PPSV23 doses should be maintained. A meta-analysis from 2008 found strong evidence that pneumococcal vaccine decreases risk for invasive pneumococcal disease (eg, bacteremia and meningitis) (OR 0.26, 95% CI 0.15-0.46) but did not demonstrate reduction in all cause pneumonia or mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Herpes zoster vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes zoster or shingles, due to reactivation of latent varicella zoster virus, causes a painful localized rash. Sequelae, including post-herpetic neuralgia, encephalitis, myelitis, and palsies of cranial and peripheral nerves, are more common in older patients. Herpes zoster affects about 30 percent of individuals over their lifetime, with a substantial increase in risk (8- to 10-fold) in late life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A vaccine for immunocompetent adults over 60 years of age was US FDA approved in 2006 to prevent herpes zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/42\">",
"     42",
"    </a>",
"    ]. It was FDA-approved for use in persons 50 to 59 years of age in 2011. The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    was also approved in the countries of the European Union by the European Medicines Agency (EMA) in 2006 for immunocompetent adults 50 years of age or older. The zoster vaccine contains more than 14 times the number of plaque-forming units of virus than does the",
"    <span class=\"nowrap\">",
"     Oka/Merck",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    for prevention of varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial in 38,500 adults over 60 years of age,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    , compared with placebo, reduced the three-year incidence of herpes zoster and postherpetic neuralgia by 51 and 67 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/43\">",
"     43",
"    </a>",
"    ]. In a large retrospective cohort study, vaccination reduced the risk of herpes zoster by 55 percent, with risk reduction seen in both healthy older adults and those with chronic disease such as diabetes or coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ACIP recommends herpes zoster vaccination for all immunocompetent persons age 60 years and older, regardless of history of varicella (chickenpox) or documentation of varicella immunity, for the prevention of herpes zoster and postherpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the ACIP declined to recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    for adults 50 to 59 years old, citing concerns regarding zoster vaccine shortfalls for general use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/46\">",
"     46",
"    </a>",
"    ]. The vaccine should not be used for the treatment of zoster or postherpetic neuralgia.",
"   </p>",
"   <p>",
"    Vaccine storage requires freezing, and the vaccine must be administered within 30 minutes of thawing, suggesting a practical need for specified sessions for vaccine administration in",
"    <span class=\"nowrap\">",
"     clinics/medical",
"    </span>",
"    offices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\", section on 'Clinical trial data on zoster vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical and surgical interventions have led to a decline in the age-specific mortality rates of many malignancies, including breast, colorectal, and cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/47\">",
"     47",
"    </a>",
"    ]. Screening asymptomatic adults for these diseases has allowed more effective treatment through early detection.",
"   </p>",
"   <p>",
"    However, both screening tests and disease treatment have been less rigorously evaluated in older adults, leading to more uncertainty about the benefit of screening among older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Additionally, comorbid illness and frailty alter the risk-benefit ratio for screening in this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to offer cancer screening to the older patient presents a clinical challenge. Clinicians should assess the benefits and risks of screening for older adults on an individual basis, considering the patient&rsquo;s estimated remaining life expectancy, and help patients make decisions based on personal values and preferences (",
"    <a class=\"graphic graphic_table graphicRef55970 \" href=\"mobipreview.htm?20/40/21133\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/48,51\">",
"     48,51",
"    </a>",
"    ]. Specific consideration should be given to colorectal, breast, and cervical cancer screening as interventions likely to be most effective in reducing cancer-specific mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ideal rate of cancer screening among the older adult population remains unclear. In a sample of 1700 noninstitutionalized adults 75 to 79 years old in the United States, screening rates exceeded 50 percent for common cancers (colorectal 57 percent, breast 62 percent, cervical 53 percent, and prostate 56 percent); whether this screening was appropriately targeted to individuals who would likely benefit from early detection and treatment of cancer is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prostate cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPSTF updated its recommendations in 2012 to recommend that men not be screened for prostate cancer, concluding that there is moderate certainty that the benefits of such screening do not outweigh the harms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/56\">",
"     56",
"    </a>",
"    ]. The ACP recommends individual discussion of the risks and benefits of prostate cancer screening and suggests that men between the ages of 50 to 69 years are most likely to benefit from screening. Black men and men with a positive family history of prostate cancer should be informed of their higher lifetime risk, although the available evidence does not suggest that they need to be treated differently from men at average risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/57\">",
"     57",
"    </a>",
"    ]. Randomized controlled trials indicate little benefit in prostate cancer specific mortality within 10 years of screening and no discernible benefit in overall mortality out to 14 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Given high rates of side effects associated with treating potentially-inconsequential, screen-detected prostate cancer, older adult men appear to have little to gain from routine screening, particularly if they have less than 10 years of life expectancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2954742\">",
"    <span class=\"h3\">",
"     Colorectal cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence supporting screening for colorectal cancer is strongest, with randomized controlled trials of fecal occult blood testing associated with a 15 to 20 percent decrease in cancer specific mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Screening test options for colorectal cancer include colonoscopy, CT colonography (\"virtual colonoscopy\"), flexible sigmoidoscopy, stool testing for blood (guaiac or immunochemical), or stool DNA testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given its ability to visualize the entire colon, colonoscopy has become the invasive screening procedure of choice. Studies, however, suggest that sigmoidoscopy may be as effective and possibly safer than colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Significant complications (bleeding and bowel perforation) occurred in 0.3 percent of 600 veterans aged 70 to 75 undergoing screening with colonoscopy, compared to 0.01 percent for sigmoidoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current recommendations from the USPSTF suggest offering colorectal cancer screening to average-risk individuals aged 50 to 75 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/67\">",
"     67",
"    </a>",
"    ]. The USPSTF recommends against screening for adults older than age 85 years and against routine screening for adults 76 to 85 years of age, though specific considerations may support colorectal cancer screening for some individuals in this age group. Patients with cardiopulmonary disease or poor functional status who are expected to live long enough to benefit from screening might be considered for CT colonography as a preferred initial screening test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link&amp;anchor=H21#H21\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Screening in older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2954749\">",
"    <span class=\"h3\">",
"     Breast cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective controlled trials of screening mammography for breast cancer demonstrate an approximate 30 percent reduction in breast cancer mortality among screened versus unscreened women. However, these studies enrolled women only up to ages 70 to 74 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Guidelines are vague on breast cancer screening for older women, but the AGS recommends offering screening every one to two years for women with a life expectancy of &ge;4 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2954756\">",
"    <span class=\"h3\">",
"     Cervical cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer is no more aggressive in older women than younger women, and high-grade lesions are rare among older women who have been previously screened. Nonetheless, older women who have never been screened have the highest incidence of and mortality from cervical cancer and benefit the most from screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/71-75\">",
"     71-75",
"    </a>",
"    ]. In the US, Medicare began providing reimbursement for Pap smear screening in 1990, motivated by findings that up to 40 percent of older adult women had never had a Pap smear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/76-79\">",
"     76-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most major guidelines recommend stopping cervical cancer screening at age 65 for women who have had adequate recent screening. Adequate screening is defined as three consecutive negative cytology tests or two consecutive negative",
"    <span class=\"nowrap\">",
"     HPV/Pap",
"    </span>",
"    co-tests in the 10 years prior to stopping, with the most recent test within five years. Women who have had a total hysterectomy for indications unrelated to cervical cancer should not undergo screening for cervical cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H23#H23\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Discontinuing screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H26#H26\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Prior hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood pressure screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is highly prevalent among older adults (60 to 80 percent) and remains the leading risk factor for ischemic heart disease and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older adults have a unique blood pressure pattern, with isolated systolic hypertension affecting two-thirds of those with elevated blood pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) emphasizes the importance of systolic blood pressures as a risk factor for cardiovascular disease and stroke, especially in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of hypertension has contributed to a 59 percent reduction in age-adjusted stroke mortality and a 50 percent reduction in mortality from coronary artery disease since 1972 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/82\">",
"     82",
"    </a>",
"    ]. Blood pressure treatment trials in older adults have consistently demonstrated significantly decreased all-cause mortality, cardiovascular events, stroke, and chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. A meta-analysis of trials including participants over age 80 demonstrated reductions in stroke, heart failure, and major cardiovascular events with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/86\">",
"     86",
"    </a>",
"    ]. Treatment options include diet, physical activity, and pharmacotherapy to lower blood pressure to goal and thereby reduce morbidity and mortality related to HTN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major authorities (USPSTF, Canadian Task Force, the American College of Physicians, the American Academy of Family Practice, and the American Geriatrics Society) recommend periodic testing of blood pressure with intervals ranging from one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/87\">",
"     87",
"    </a>",
"    ]. The ACP and ACOVE recommend annual screening for all older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concern has been raised in the past about the risks of aggressive treatment of hypertension in older adults, including orthostatic hypotension, falls, renal dysfunction, electrolyte disturbance, and, in small studies, increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/86,88\">",
"     86,88",
"    </a>",
"    ]. The benefits of treatment, however, are likely to outweigh risks for many patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/89\">",
"     89",
"    </a>",
"    ]. Among frail older adults (defined as gait speed &lt;0.8",
"    <span class=\"nowrap\">",
"     m/second),",
"    </span>",
"    though, an observational study found no association between blood pressure and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/90\">",
"     90",
"    </a>",
"    ]. In addition, a higher blood pressure was associated with a lower risk of death among the most frail (ie, those who could not walk well enough to test gait speed). The expected association of a higher blood pressure with a greater mortality risk was observed only among the most fit individuals.",
"   </p>",
"   <p>",
"    Care should be taken to avoid complications when treatment is undertaken:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial treatment should involve trials of nonpharmacologic measures, such as reduction of salt, weight loss, and discontinuing medications that increase blood pressure (eg, nonsteroidal antiinflammatory drugs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If pharmacologic therapy is necessary, initiate medication at very low doses.",
"     </li>",
"     <li>",
"      Monitor prescription adherence, renal function, electrolytes, orthostatic blood pressure and pulse, and assess for gait instability and falls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lipid screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of CHD attributable to lipids is similar across age ranges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/92\">",
"     92",
"    </a>",
"    ]. Older adults have a higher overall annual risk of CHD and stand to benefit from lipid reduction if life expectancy warrants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10760?source=see_link\">",
"     \"Treatment of dyslipidemia in the older adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The USPSTF has found good evidence that lipid measurement can identify asymptomatic people at increased risk of coronary heart disease, and good evidence that lipid lowering drug therapy decreases the incidence of coronary heart disease in people with abnormal lipids and causes few major harms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/17\">",
"     17",
"    </a>",
"    ]. The Task Force concludes that the benefits of screening for and treating lipid disorders in older people outweigh harms.",
"   </p>",
"   <p>",
"    Lipid lowering therapy clearly benefits older adults at high risk of coronary events. The benefit of primary prevention for low-risk older adults remains unclear. For those with an overall risk of CHD exceeding 10 percent over 10 years, screening and treatment appear to be substantiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of low bone mineral density in older adults is high. Osteopenia is found in 37 percent of post-menopausal women, and osteoporosis (bone mineral density or BMD &gt;2.5 SD below the mean for young women) in 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF recommends that women aged 65 and older be screened routinely for osteoporosis using bone densitometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/95\">",
"     95",
"    </a>",
"    ]. The USPSTF also recommends that routine screening begin at age 60 for women at increased risk for osteoporotic fractures, including those with low body weight. Questions remain about how frequently women should be screened and when to stop offering bone densitometry. Varying recommendations for screening from several expert groups are presented in a table (",
"    <a class=\"graphic graphic_table graphicRef62866 \" href=\"mobipreview.htm?0/52/846\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Physicians recommends periodic assessment of men for risk factors for osteoporosis (low body weight, physical inactivity, chronic glucocorticoid therapy, previous fragility fracture, hypogonadism) and DEXA scanning for men who are at increased risk and are candidates for drug treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/96\">",
"     96",
"    </a>",
"    ]. ACOVE authors also recommend offering DEXA scanning to men over age 65 at high risk of osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Abdominal aortic aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for abdominal aortic aneurysm (AAA) with a one-time abdominal ultrasound examination has been shown to decrease aneurysm-related deaths and all-cause mortality in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Because the prevalence of AAA is lower in women, screening has not been shown to be effective in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking increases the risk for AAA. One-time ultrasonography screening for abdominal aortic aneurysm (AAA) is recommended by several organizations (the USPSTF and the American Heart Association) for men ages 65 to 75 who have ever smoked. The USPSTF recommends against routine screening for AAA in women and made no recommendation for or against screening for AAA in men ages 65 to 75 who have never smoked. We also recommend screening at ages 65 to 75 for those who have never smoked but who have a first-degree relative who required repair of an AAA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=see_link\">",
"     \"Screening for abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aneurysmal repair should be considered for asymptomatic aneurysms that are more than twice the size of the normal segment and for aneurysms with enlarging diameter at follow-up. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TERTIARY PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Functional assessment and geriatric evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impairment in activities of daily living is associated with an increased risk of falls, depression, institutionalization, and death in the affected older adult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Obtaining a history of functional status, with particular attention to activities of daily living (eg, bathing, toileting, grooming, meal preparation) allows the clinician to focus in on potential problem areas. Asking questions targeted at specific conditions that impact function and quality of life may well reduce the morbidity related to these problems (",
"    <a class=\"graphic graphic_table graphicRef64158 \" href=\"mobipreview.htm?12/20/12622\">",
"     table 3",
"    </a>",
"    ). In addition, measurement of gait speed identifies older adults at high risk of functional decline and poor health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/103\">",
"     103",
"    </a>",
"    ]. A gait speed faster than 1",
"    <span class=\"nowrap\">",
"     meter/second",
"    </span>",
"    suggests better than average life expectancy.",
"   </p>",
"   <p>",
"    Comprehensive Geriatric Assessment (CGA) can provide a more formal means of identifying key problems and can inform interventions that result in reduced functional decline and improved quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. However, CGA can be impractical and time consuming in the primary care setting.",
"   </p>",
"   <p>",
"    The following sections identify key components of the CGA and other practical suggestions for identification of common problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43624?source=see_link\">",
"     \"Comprehensive geriatric assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cognitive assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of dementia increases with age, with estimates ranging from 20 to 50 percent after age 85 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Early or mild dementia may remain undetected without specific screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/108\">",
"     108",
"    </a>",
"    ]. No evidence exists that screening for early or mild dementia results in improved clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of instruments, including the Mini Mental Status Examination (MMSE), Clock Drawing Test, Mini-Cog and Memory Impairment Screen, are validated screening tools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/109\">",
"     109",
"    </a>",
"    ]. Validated instruments also exist for collecting data regarding patient function from a relative or caregiver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is lack of consensus on the value of screening. Vulnerable older adults may benefit from screening if early identification results in preservation of function and increased attention to safety, behavioral, and caregiver issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/109,111\">",
"     109,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF and the American Academy of Neurology (AAN) do not support screening asymptomatic older adults for dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. We suggest that physicians perform targeted screening for older adults with memory complaints",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    newly recognized functional impairment, either self-expressed or noted by a caregiver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-life depression often goes undetected and has a significant adverse impact on quality of life, outcomes of medical disease, healthcare utilization, morbidity, and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/115\">",
"     115",
"    </a>",
"    ]. Suicide rates are almost twice as high in the older adult compared with the general population, with the rate highest for white men over 85 years of age.",
"   </p>",
"   <p>",
"    The overwhelming majority of older adults with depression initially present to primary care, often with somatic complaints. Among older adults, depression can present atypically with cognitive, functional, or sleep problems as well as complaints of fatigue or low energy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several short screening instruments have been developed and validated for screening for depression in older adults. Asking two simple questions about mood and anhedonia (\"Over the past two weeks have you felt down, depressed, or hopeless?\" and \"Over the past two weeks have you felt little interest or pleasure in doing things?\") may be as effective a screening tool for depression as longer instruments. Any positive screening tests should trigger a full diagnostic interview. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The USPSTF and ACOVE authors recommend screening all adults for depression, although the optimal screening interval is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. They also emphasize the importance of having systems in place to provide feedback of screening results, a readily accessible means of making accurate diagnosis, and a mechanism for providing treatment and careful follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vision screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased visual acuity increases fall risk and was an independent predictor of all-cause mortality in one study. It has not been determined if correcting visual impairments would reduce mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Long-Term Care Survey (NLTCS) found that more regular eye examinations correlated with lower probability of low vision or blindness and improved functional status in a sample of 14,215 Medicare beneficiaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/120\">",
"     120",
"    </a>",
"    ]. However, a systematic review found no evidence that screening by self-reported history of visual problems improves vision in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/121\">",
"     121",
"    </a>",
"    ]. Several randomized trials of older adults seen in primary care found that vision screening (usually Snellen chart testing for visual acuity) was not more effective than no screening or usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/122-124\">",
"     122-124",
"    </a>",
"    ], and one trial found that optometry screening increased the risk for falls in frail older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cataract surgery has been shown to improve cognition, depression, and vision-related quality of life in older patients with cataracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/126\">",
"     126",
"    </a>",
"    ]. Early intervention for age-related macular degeneration seems to be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=see_link\">",
"     \"Age-related macular degeneration: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the implications for function and safety, the ACOVE authors suggest a general ophthalmologic examination every one to two years, acknowledging the lack of prospective data to support this recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/127\">",
"     127",
"    </a>",
"    ]. A systematic review of randomized trials, prepared for the USPSTF, concluded that further studies are needed to understand why trials of vision screening have not shown benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/128\">",
"     128",
"    </a>",
"    ]. The 1996 USPSTF guidelines recommended Snellen acuity testing in older adults, but in the 2009 revision the USPSTF concluded that evidence is insufficient to determine whether screening older adults for visual impairment improves functional outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for glaucoma screening vary by organization. There is general agreement that older patients should be screened every one to two years by an eye professional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/130\">",
"     130",
"    </a>",
"    ]; the appropriate age to initiate screening is not certain, and may depend on risk factors including positive family history and African Americans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=see_link&amp;anchor=H447095064#H447095064\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant changes in vision and hearing occur in most patients as they age. Hearing loss is associated with depression, social isolation, poor self-esteem, and functional disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41896?source=see_link\">",
"     \"Presbycusis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hearing loss is the third most common ailment in older adults (behind hypertension and arthritis), affecting an estimated 40 to 66 percent of those over age 75. Patient inquiry is a rapid and inexpensive way to screen for hearing loss. While pure tone audiometry is the reference standard for screening hearing, a whispered voice test is sensitive and specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/133\">",
"     133",
"    </a>",
"    ]. An evidence review to support a recommendation from the US Preventive Services Task Force (USPSTF) found that either the whispered voice test at two feet or a single question regarding perceived hearing loss were nearly as effective as a formal hearing questionnaire or use of a tone-emitting otoscope for the detection of hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/134\">",
"     134",
"    </a>",
"    ]. In 2012, the USPSTF concluded that there was insufficient evidence to determine the balance or benefits and harms of screening for hearing loss in asymptomatic older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/135\">",
"     135",
"    </a>",
"    ]. A randomized controlled trial in an older US veteran population demonstrated that patients screened with a combination of a questionnaire and a tone-emitting otoscope, compared with either assessment alone, had higher adherence to referral to audiology and use of hearing aids at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of hearing loss in adults\", section on 'Office hearing evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACOVE authors suggest an annual hearing screen by questionnaire and handheld audiometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/132\">",
"     132",
"    </a>",
"    ]. Formal audiometry need not be performed if the patient is unwilling or unable to use assisted devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many major authorities on health care maintenance, including the Canadian Task Force, the American College of Physicians (ACP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/137\">",
"     137",
"    </a>",
"    ], and the American Academy of Family Physicians (AAFP), recommend that clinicians routinely provide nutritional assessment and counseling to their patients. A mini-nutritional assessment tool has been developed to help the clinician determine patients who may need nutritional support and counseling (",
"    <a class=\"graphic graphic_figure graphicRef79831 \" href=\"mobipreview.htm?5/35/5685\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approximately 15 percent of older outpatients and half of the hospitalized older adults are malnourished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/138\">",
"     138",
"    </a>",
"    ]. Despite the clear relationship between undernutrition and increased morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/139\">",
"     139",
"    </a>",
"    ], there are no well-validated general laboratory screens for this condition. A combination of serial weight measurements obtained in the office and inquiry about changing appetite are likely the most useful methods of assessing nutritional status in older patients.",
"   </p>",
"   <p>",
"    Vulnerable older adults with an involuntary weight loss of 10 percent or more in less than a year should undergo further evaluation for undernutrition, possible medical or medication-related causes, dental status, food security, food related functional status, appetite and intake, swallow ability, and previous dietary restrictions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/140\">",
"     140",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31946?source=see_link\">",
"     \"Geriatric nutrition: Nutritional issues in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2634929\">",
"    <span class=\"h3\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the large Women's Health Initiative found that calcium and vitamin D was not effective in reducing fractures in healthy postmenopausal women over a seven year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/141\">",
"     141",
"    </a>",
"    ], meta-analysis of eight trials found that vitamin D with calcium decreased the relative risk (RR) for hip fractures (RR 0.84, 95% CI 0.73-0.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/142\">",
"     142",
"    </a>",
"    ]. Another meta-analysis found a significant reduction in the incidence of hip (RR 0.70, 95% CI 0.58-0.86) and nonvertebral (RR 0.86, 95% CI 0.76-0.96) fracture in individuals with a median vitamin D intake of 800 IU daily, compared with controls who took placebo or calcium alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A growing evidence base has identified the high prevalence of vitamin D deficiency (&lt;30",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    among older adults and important health implications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/144\">",
"     144",
"    </a>",
"    ]. Vitamin D reduces the relative risk of falls by 22 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/145\">",
"     145",
"    </a>",
"    ]. The daily intake of vitamin D in older adults should be at least 800 to 1000 IU. At least 1.2 g of elemental calcium in the diet or as a supplement is also recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2634936\">",
"    <span class=\"h3\">",
"     Multivitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;No prospective randomized data supports an effect of multivitamins on morbidity or mortality. Multivitamin supplementation has the potential to provide benefit for those older individuals whose nutritional intake is insufficient. However, observational studies have suggested that multivitamin supplements do not decrease the risk for cancer or cardiovascular disease, and one large cohort study suggested the possibility of increased mortality in healthy older women who reported taking vitamin supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/146\">",
"     146",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Falls and mobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of noninstitutionalized older adults fall each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/147\">",
"     147",
"    </a>",
"    ]. The annual incidence of falls approaches 50 percent in patients over 80 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/148\">",
"     148",
"    </a>",
"    ]. Five percent of falls in older adults result in fracture or hospitalization.",
"   </p>",
"   <p>",
"    Factors contributing to falls include age-related postural changes, decreased vision, cognitive impairment, certain medications (particularly anticholinergic, psychotropic, and cardiovascular medications), diseases affecting muscle strength and coordination, and environmental factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/149\">",
"     149",
"    </a>",
"    ]. Effective interventions for people with a history of falls or who are at risk for falling involve addressing multiple contributing factors (",
"    <a class=\"graphic graphic_table graphicRef82170 \" href=\"mobipreview.htm?37/30/38379\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef69682 \" href=\"mobipreview.htm?29/50/30496\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/150\">",
"     150",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Providers should regularly inquire about the occurrence of recent falls in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/151\">",
"     151",
"    </a>",
"    ]. For patients who report falling, basic assessment should include review of circumstances of the fall(s), measure of orthostatic vital signs, visual acuity testing, cognitive evaluation, and gait and balance assessment (",
"    <a class=\"graphic graphic_algorithm graphicRef69682 \" href=\"mobipreview.htm?29/50/30496\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/151-153\">",
"     151-153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A straightforward physical examination maneuver called the \"Get Up and Go\" test has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/154\">",
"     154",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef66046 \" href=\"mobipreview.htm?5/47/5885\">",
"     table 5",
"    </a>",
"    ). In this test, the patient is instructed to arise from a sitting position, walk 10 feet, turn, and return to the chair to sit. A requirement of more than 16 seconds to complete the process, or observation of postural instability or gait impairment, suggests an increased risk of falling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Providers should also review all medications (with particular attention to hypnotic and other psychotropic drugs) for possible causative agents and inquiry about home safety. Appropriate patients should be evaluated for assistive devices and a supervised exercise program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/156\">",
"     156",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence (UI) causes major social and emotional distress in older adults and is a major factor in nursing home placement. UI is estimated to affect 11 to 34 percent of older men and 17 to 55 percent of older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/157\">",
"     157",
"    </a>",
"    ]. Diabetes approximately doubles the risk for severe incontinence in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/158\">",
"     158",
"    </a>",
"    ]. Continence problems are frequently treatable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/159\">",
"     159",
"    </a>",
"    ] but are often not raised by patients as a concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A targeted history and physical examination can often identify the cause of UI and lead to appropriate intervention. ACOVE authors recommend asking about and documenting the presence or absence of UI biannually, and determining whether the UI, if present, is bothersome to the patient or caregiver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/161\">",
"     161",
"    </a>",
"    ]. Appropriate assessment includes questions to determine UI onset (acute versus chronic), type (eg, stress, urge, overflow, mixed), and precipitants (eg, cough, medication use). A targeted physical might include assessment for fluid overload, genital and rectal examination, and neurologic evaluation. Urine and blood tests are indicated to evaluate for infection, metabolic causes, renal dysfunction, and possible vitamin B12 deficiency. Routine urodynamic testing is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     MEDICATION USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems related to medication use are common in older adults. Adults over age 65 in the United States take an average of three to five medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/162\">",
"     162",
"    </a>",
"    ]. Use of multiple medications increases the risk for drug-drug interactions and associated adverse drug events. Altered pharmacokinetics and pharmacodynamics in older adults contribute to adverse drug events, a common cause of hospitalization and morbidity in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/163\">",
"     163",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=see_link\">",
"     \"Drug prescribing for older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence-based recommendations on medication management, evaluated by ACOVE authors, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain an up-to-date medication list, including over-the counters and herbals.",
"     </li>",
"     <li>",
"      Comprehensively review medications at least once annually (if not at every visit) and after all hospitalizations. A clear indication for each medication, and documentation of response to therapy (particularly for chronic conditions), should be included.",
"     </li>",
"     <li>",
"      Assess for duplication, drug-drug or drug-disease interactions, adherence, and affordability.",
"     </li>",
"     <li>",
"      Assess for specific classes of medications commonly associated with adverse events:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , analgesics (particularly narcotics and NSAIDs), antihypertensives (particularly ACE inhibitors and diuretics), insulin and hypoglycemic agents, and any psychotropics.",
"     </li>",
"     <li>",
"      Minimize or avoid use of anticholinergic medications which present specific risks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Beer&rsquo;s Criteria for Potentially Inappropriate Medication Use in Older Adults also provides a list of commonly encountered problem medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DRIVING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults over age 70 suffer more motor vehicle accidents (MVA) and more fatal driver and pedestrian accidents per one million miles driven than middle-aged drivers. This is likely a result of factors such as a decline in visual acuity, hearing, and psychomotor skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/165\">",
"     165",
"    </a>",
"    ]. The American Medical Association (AMA) offers a specific online publication to guide assessment of the older driver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/166\">",
"     166",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3385?source=see_link\">",
"     \"Approach to the evaluation of older drivers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of dementia independently increases the risk of an MVA (OR 2.4 to 4.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/167\">",
"     167",
"    </a>",
"    ]. Clinicians should discuss driving with all patients diagnosed with dementia and either recommend stopping driving or refer for formal driving assessment by occupational therapy. Specific reporting laws vary by state. The American Academy of Neurology has issued guidelines for driving in patients with Alzheimer disease based upon the clinical dementia rating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/168\">",
"     168",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4552?source=see_link\">",
"     \"Safety and societal issues related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     FINANCIAL AND SOCIAL SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The older adult US population varies widely in measures of wealth and social support. While the overall rate of poverty among adults over age 65 has declined over the last 50 years, 10 percent of older adults still live at or below the poverty line, with higher rates among blacks (24 percent) and Hispanics (21 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older adults also suffer from social isolation, due to functional limitations, and lack of relatives, friends, or organizations to provide physical or emotional support needed to maintain independence and well-being. Social isolation and poverty are associated with high rates of depression, anxiety, disability, and self-rated poor health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/169\">",
"     169",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Providers should screen for problems with financial and social resources as these issues have direct implications for health status and well-being. Most communities have assistance available through Area Agencies on Aging or other municipal organizations. Information can be gathered online at",
"    <a class=\"external\" href=\"file://www.eldercare.gov/eldercare.NET/Public/index.aspx\">",
"     eldercare.gov",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     ELDER MISTREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elder mistreatment has been reported in 3 to 8 percent of the older adult population in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/170\">",
"     170",
"    </a>",
"    ]. A variety of forms of neglect or physical abuse (physical, sexual, psychological, financial, neglect) can result in adverse health outcomes for older victims, including increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/171\">",
"     171",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17850?source=see_link\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Victims themselves are unlikely to report instances of abuse, making it difficult to address issues in the clinical setting. Older adults who are noted to have contusions, burns, bite marks, genital or rectal trauma, pressure ulcers, or a BMI &lt;17.5 without clinical explanation should be asked about mistreatment or referred to social work services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/3\">",
"     3",
"    </a>",
"    ]. Available screening tools may also help clinicians discriminate cases of abuse or neglect. The American Medical Association and the USPSTF recommend that physicians routinely ask older patients direct, specific questions about abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/117,172\">",
"     117,172",
"    </a>",
"    ], although the USPSTF finds insufficient evidence to recommend for or against the use of screening instruments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ADVANCE DIRECTIVES AND HEALTH CARE PROXY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of end-of-life care is well-suited to the health maintenance examination when the focus may be less on specific disease and more on prevention and planning. Older patients may experience periods of altered sensorium or cognitive impairment and become unable to participate in their financial or health care decisions. Powers of attorney, living wills, advanced directives, and guardianship documents become important in these situations.",
"   </p>",
"   <p>",
"    A power of attorney designates a surrogate who is authorized to manage a patient's financial affairs. A health care power of attorney designates a representative to make health care choices for the patients. For patients who have not created a health care power of attorney, the spouse or other first-degree relative typically is the default surrogate decision-maker. The patient's preferences are sometimes detailed in a living will or other more detailed advance directive. This document may address situations in which the patient has a terminal illness, persistent vegetative state, or progressive neurologic condition and can include explicit directions for care management including withdrawal or withholding specific measures such as artificial nutrition or hydration. If no surrogate is designated and next-of-kin is not available, guardianship may be obtained. Guardianship is a legal proceeding whereby the court appoints a surrogate decision-maker. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a number of years, the United States Preventive Services Task Force (USPSTF) has developed and revised specific clinical recommendations regarding health maintenance for all populations in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the last decade, several resources have emerged to define priorities for prevention and promotion specifically among older adults. Healthy People 2010 (HP2010) defines specific targets for the older adult population nationwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/173\">",
"     173",
"    </a>",
"    ]. The Centers for Disease Control (CDC), with the support of the Merck Foundation, published its annual State of Aging report, which focuses on specific problem areas for intervention and cites the HP2010 goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Assessing Care of Vulnerable Elders (ACOVE-3) project identifies quality indicators, including routine health maintenance, in the care of older adults, with a particular focus for those in frail health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines with regard to interval screening for specific malignancies are available from the USPSTF and from the American Cancer Society (ACS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/48,117\">",
"     48,117",
"    </a>",
"    ] and others. ACS recommendations are generally more supportive of cancer screening programs than are those of other groups.",
"   </p>",
"   <p>",
"    The American Geriatric Society offers an online archive of information related to geriatric screening and health maintenance issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/18/38186/abstract/175\">",
"     175",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information on legal issues and the older patient is available from the National Academy of Elder Law Attorneys at",
"    <a class=\"external\" href=\"file://www.naela.org/\">",
"     www.naela.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PATIENT RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Agency for Healthcare Research and Quality has prepared a booklet for older adults called \"The Pocket Guide to Staying Healthy at 50+.\" It is available on the web at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/ppip/50plus\">",
"     www.ahrq.gov/ppip/50plus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Through its Health in Aging Foundation, the American Geriatrics Society has created an informational website for patients and carers at",
"    <a class=\"external\" href=\"file://www.healthinaging.org/\">",
"     www.healthinaging.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The National Institute on Aging provides free pamphlets, as part of its Age Pages series, on other common issues in older adults. They are available at",
"    <a class=\"external\" href=\"file://www.niapublications.org/shopdisplayproducts.asp?id=45&amp;cat=All+Age+Pages\">",
"     www.niapublications.org/shopdisplayproducts.asp?id=45&amp;cat=All+Age+Pages",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/54/867?source=see_link\">",
"       \"Patient information: Preventive healthcare for older adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decline in function and loss of independence are NOT an inevitable consequence of aging. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple age-related conditions are amenable to prevention or amelioration with screening, counseling, and appropriate intervention. A summary of recommendations for specific conditions is presented in a table (",
"      <a class=\"graphic graphic_table graphicRef75220 \" href=\"mobipreview.htm?12/12/12494\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Primary Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Secondary Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Tertiary Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention and The Merck Company Foundation. The State of Aging and Health in America 2007. The Merck Company Foundation, Whitehouse Station, NJ 2007. Available at: file://www.cdc.gov/aging/pdf/saha_2007.pdf (Accessed on April 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/2\">",
"      Cigolle CT, Langa KM, Kabeto MU, et al. Geriatric conditions and disability: the Health and Retirement Study. Ann Intern Med 2007; 147:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/3\">",
"      Gnanadesigan N, Fung CH. Quality indicators for screening and prevention in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/4\">",
"      Schonberg MA, Leveille SG, Marcantonio ER. Preventive health care among older women: missed opportunities and poor targeting. Am J Med 2008; 121:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/5\">",
"      Pham HH, Schrag D, Hargraves JL, Bach PB. Delivery of preventive services to older adults by primary care physicians. JAMA 2005; 294:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/6\">",
"      Reuben DB. Medical care for the final years of life: \"When you're 83, it's not going to be 20 years\". JAMA 2009; 302:2686.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Healthy People 2010, conference edition. Washington DC: U.S. Department of Health and Human Services; 2000. Available at: www.healthypeople.gov (Accessed on December 21, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/8\">",
"      King AC, Guralnik JM. Maximizing the potential of an aging population. JAMA 2010; 304:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/9\">",
"      Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/10\">",
"      Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials. Frailty and Injuries: Cooperative Studies of Intervention Techniques. JAMA 1995; 273:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/11\">",
"      Wolfson L, Whipple R, Derby C, et al. Balance and strength training in older adults: intervention gains and Tai Chi maintenance. J Am Geriatr Soc 1996; 44:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/12\">",
"      Wolf SL, Barnhart HX, Kutner NG, et al. Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention Techniques. J Am Geriatr Soc 1996; 44:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/13\">",
"      Doolan DM, Froelicher ES. Efficacy of smoking cessation intervention among special populations: review of the literature from 2000 to 2005. Nurs Res 2006; 55:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/14\">",
"      Burns DM. Cigarette smoking among the elderly: disease consequences and the benefits of cessation. Am J Health Promot 2000; 14:357.",
"     </a>",
"    </li>",
"    <li>",
"     Health benefits of smoking cessation: a report of the Surgeon General 1990. Centers for Disease Control; Office on Smoking and Health, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/16\">",
"      Russell MA, Wilson C, Taylor C, Baker CD. Effect of general practitioners' advice against smoking. Br Med J 1979; 2:231.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Guide to Clinical Preventive Services. Available at: www.ahrq.gov/clinic/3rduspstf/aspirin/asprr.htm (Accessed on January 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/18\">",
"      Elhassan A, Chow RD. Smoking cessation in the elderly. Clin Geriatr 2007; 15:38.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical guidelines for alcohol use disorders in older adults. American Geriatrics Society (AGS) Position Statement. American Geriatrics Society, New York 2003.",
"    </li>",
"    <li>",
"     Helping Patients Who Drink Too Much, a Clinician's Guide. 2005. Available at: www.niaaa.nih.gov/guide (Accessed on January 10, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/21\">",
"      Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/22\">",
"      Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/23\">",
"      Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/24\">",
"      Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged &gt; or =70. BMJ 2005; 330:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/25\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Tetanus--Kansas, 1993. MMWR Morb Mortal Wkly Rep 1994; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/27\">",
"      Solomonova K, Vizev S. Secondary response to boostering by purified aluminium-hydroxide-adsorbed tetanus anatoxin in aging and in aged adults. Immunobiology 1981; 158:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/28\">",
"      Balestra DJ, Littenberg B. Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis. J Gen Intern Med 1993; 8:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/29\">",
"      Marlovits S, Stocker R, Efstratiou A, et al. Effect on diphtheria immunity of combined tetanus and diphtheria booster vaccination in adults. Eur J Clin Microbiol Infect Dis 2000; 19:506.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/recs/acip/slides-oct10.htm (Accessed on November 10, 2010).",
"    </li>",
"    <li>",
"     file://www.reuters.com/article/idUSTRE69Q5UL20101027  (Accessed on November 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/33\">",
"      Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/34\">",
"      Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/35\">",
"      Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/36\">",
"      Simonsen L, Reichert TA, Viboud C, et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/37\">",
"      Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:1373.",
"     </a>",
"    </li>",
"    <li>",
"     CDC's Advisory Committee on Immunization Practices (ACIP) recommends universal annual influenza vaccination. Available at: file://www.cdc.gov/media/pressrel/2010/r100224.htm (Accessed on May 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged &gt;or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/40\">",
"      Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; :CD000422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/41\">",
"      Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/42\">",
"      Mitka M. FDA approves shingles vaccine: herpes zoster vaccine targets older adults. JAMA 2006; 296:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/43\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/44\">",
"      Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/45\">",
"      Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011; 60:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/47\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/48\">",
"      Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/49\">",
"      Albert RH, Clark MM. Cancer screening in the older patient. Am Fam Physician 2008; 78:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/50\">",
"      Clarfield AM. Screening in frail older people: an ounce of prevention or a pound of trouble? J Am Geriatr Soc 2010; 58:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/51\">",
"      Alibhai SMH, Horgan AM. Cancer screening in older adults: What to do when we don't know. J Geriatr Oncol 2011; 2:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/52\">",
"      Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med 2005; 118:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/53\">",
"      Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007; 57:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/54\">",
"      Bellizzi KM, Breslau ES, Burness A, Waldron W. Prevalence of cancer screening in older, racially diverse adults: still screening after all these years. Arch Intern Med 2011; 171:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/55\">",
"      Walter LC. What is the right cancer screening rate for older adults. Arch Intern Med 2011; 171:2037.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatefinalrs.htm (Accessed on May 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/57\">",
"      Screening for prostate cancer. American College of Physicians. Ann Intern Med 1997; 126:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/58\">",
"      Hugosson J, Carlsson S, Aus G, et al. Mortality results from the G&ouml;teborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/59\">",
"      Schr&ouml;der FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/60\">",
"      Scholefield JH, Moss S, Sufi F, et al. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002; 50:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/61\">",
"      Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/62\">",
"      Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/63\">",
"      J&oslash;rgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/64\">",
"      Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/65\">",
"      Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/66\">",
"      M&uuml;ller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/67\">",
"      U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/68\">",
"      Nystr&ouml;m L, Rutqvist LE, Wall S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993; 341:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/69\">",
"      Olsen O, G&oslash;tzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358:1340.",
"     </a>",
"    </li>",
"    <li>",
"     AGS Clinical Practice Committee. Available at: www.americangeriatrics.org/products/positionpapers/brstcncr.shtml (Accessed on December 20, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/71\">",
"      Sawaya GF, Sung HY, Kearney KA, et al. Advancing age and cervical cancer screening and prognosis. J Am Geriatr Soc 2001; 49:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/72\">",
"      Fletcher A. Screening for cancer of the cervix in elderly women. Lancet 1990; 335:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/73\">",
"      Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999; 318:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/74\">",
"      Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 1992; 117:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/75\">",
"      Power EJ. Pap smears, elderly women, and Medicare. Cancer Invest 1993; 11:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/76\">",
"      Celentano DD, Shapiro S, Weisman CS. Cancer preventive screening behavior among elderly women. Prev Med 1982; 11:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/77\">",
"      Mandelblatt J, Schechter C, Fahs M, Muller C. Clinical implications of screening for cervical cancer under Medicare. The natural history of cervical cancer in the elderly: what do we know? What do we need to know? Am J Obstet Gynecol 1991; 164:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/78\">",
"      Weinrich S, Coker AL, Weinrich M, et al. Predictors of Pap smear screening in socioeconomically disadvantaged elderly women. J Am Geriatr Soc 1995; 43:267.",
"     </a>",
"    </li>",
"    <li>",
"     Gluck ME, Wagner JL, Duffy BM. The use of preventive services by the elderly. Preventive Health Services under Medicare series, Paper 2. Office of Technology Assessment; Washington, DC 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/80\">",
"      Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 46:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/81\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     US Public Health Service. Clinicians Handbook of Preventive Services, 2nd ed, International Medical Publishers, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/83\">",
"      Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/84\">",
"      Min LC, Mehrotra R, Fung CH. Quality indicators for the care of hypertension in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/85\">",
"      Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2012; 344:d7541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/86\">",
"      Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353:793.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force (USPSTF). Screening for High Blood Pressure. Available at: www.ahrq.gov/clinic/uspstf07/hbp/hbprs.htm (Accessed on January 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/88\">",
"      Oates DJ, Berlowitz DR, Glickman ME, et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 2007; 55:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/89\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/90\">",
"      Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 2012; 172:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/91\">",
"      Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/92\">",
"      Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007; 5:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/93\">",
"      Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/94\">",
"      Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326:469.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force (USPSTF). Screening for Osteoporosis. Available at: www.ahrq.gov/clinic/uspstf/uspsoste.htm (Accessed on December 21, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/96\">",
"      Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/97\">",
"      Grossman J, MacLean CH. Quality indicators for the care of osteoporosis in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/98\">",
"      Ashton HA, Buxton MJ, Day NE, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002; 360:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/99\">",
"      Kim LG, P Scott RA, Ashton HA, et al. A sustained mortality benefit from screening for abdominal aortic aneurysm. Ann Intern Med 2007; 146:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/100\">",
"      Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. Br J Surg 1995; 82:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/101\">",
"      Manton KG. A longitudinal study of functional change and mortality in the United States. J Gerontol 1988; 43:S153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/102\">",
"      Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 1992; 93:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/103\">",
"      Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011; 305:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/104\">",
"      Kuo HK, Scandrett KG, Dave J, Mitchell SL. The influence of outpatient comprehensive geriatric assessment on survival: a meta-analysis. Arch Gerontol Geriatr 2004; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/105\">",
"      Cohen HJ, Feussner JR, Weinberger M, et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 2002; 346:905.",
"     </a>",
"    </li>",
"    <li>",
"     Gallo JJ, Reichel W, Andersen L. Handbook of Geriatric Assessment, Aspen Publishers, Rockville, MD 1988.",
"    </li>",
"    <li>",
"     Patterson CJ. Detecting cognitive impairment in the elderly. In: Preventing Disease: Beyond the Rhetoric, Goldbloom RB, Lawrence RS (Eds), Springer-Verlag, New York 1990. p.150.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/108\">",
"      McLean S. Assessing dementia. Part I: Difficulties, definitions and differential diagnosis. Aust N Z J Psychiatry 1987; 21:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/109\">",
"      Holsinger T, Deveau J, Boustani M, Williams JW Jr. Does this patient have dementia? JAMA 2007; 297:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/110\">",
"      Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/111\">",
"      Feil DG, MacLean C, Sultzer D. Quality indicators for the care of dementia in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/112\">",
"      U.S. Preventive Services Task Force. Screening for dementia: recommendation and rationale. Ann Intern Med 2003; 138:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/113\">",
"      Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/114\">",
"      Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/115\">",
"      Gallo JJ, Rabins PV, Lyketsos CG, et al. Depression without sadness: functional outcomes of nondysphoric depression in later life. J Am Geriatr Soc 1997; 45:570.",
"     </a>",
"    </li>",
"    <li>",
"     Depression Guidelines Panel. Depression in Primary Care: Volume 1, Detection and Diagnosis, Clinical Practice Guideline, No. 5. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Guide to Clinical Preventive Services. Available at: www.ahrq.gov/clinic/uspstfix.htm (Accessed on December 19, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/118\">",
"      Nakajima GA, Wenger NS. Quality indicators for the care of depression in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/119\">",
"      Pedula KL, Coleman AL, Hillier TA, et al. Visual acuity, contrast sensitivity, and mortality in older women: Study of osteoporotic fractures. J Am Geriatr Soc 2006; 54:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/120\">",
"      Sloan FA, Picone G, Brown DS, Lee PP. Longitudinal analysis of the relationship between regular eye examinations and changes in visual and functional status. J Am Geriatr Soc 2005; 53:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/121\">",
"      Smeeth L, Iliffe S. Community screening for visual impairment in the elderly. Cochrane Database Syst Rev 2000; :CD001054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/122\">",
"      Smeeth L, Fletcher AE, Hanciles S, et al. Screening older people for impaired vision in primary care: cluster randomised trial. BMJ 2003; 327:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/123\">",
"      Eekhof J, De Bock G, Schaapveld K, Springer M. Effects of screening for disorders among the elderly: an intervention study in general practice. Fam Pract 2000; 17:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/124\">",
"      Moore AA, Siu Al, Partridge JM, et al. A randomized trial of office-based screening for common problems in older persons. Am J Med 1997; 102:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/125\">",
"      Cumming RG, Ivers R, Clemson L, et al. Improving vision to prevent falls in frail older people: a randomized trial. J Am Geriatr Soc 2007; 55:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/126\">",
"      Ishii K, Kabata T, Oshika T. The impact of cataract surgery on cognitive impairment and depressive mental status in elderly patients. Am J Ophthalmol 2008; 146:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/127\">",
"      Rowe S, MacLean CH. Quality indicators for the care of vision impairment in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/128\">",
"      Chou R, Dana T, Bougatsos C. Screening older adults for impaired visual acuity: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/129\">",
"      U.S. Preventive Services Task Force. Screening for impaired visual acuity in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/130\">",
"      Rowe S, MacLean CH, Shekelle PG. Preventing visual loss from chronic eye disease in primary care: scientific review. JAMA 2004; 291:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/131\">",
"      Popelka MM, Cruickshanks KJ, Wiley TL, et al. Low prevalence of hearing aid use among older adults with hearing loss: the Epidemiology of Hearing Loss Study. J Am Geriatr Soc 1998; 46:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/132\">",
"      Yueh B, Shekelle P. Quality indicators for the care of hearing loss in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/133\">",
"      Pirozzo S, Papinczak T, Glasziou P. Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ 2003; 327:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/134\">",
"      Chou R, Dana T, Bougatsos C, et al. Screening adults aged 50 years or older for hearing loss: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2011; 154:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/135\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for hearing loss in older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/136\">",
"      Yueh B, Collins MP, Souza PE, et al. Long-term effectiveness of screening for hearing loss: the screening for auditory impairment--which hearing assessment test (SAI-WHAT) randomized trial. J Am Geriatr Soc 2010; 58:427.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Preventive Services Self-Evaluation Module, Appendix a-1, American Board of Internal Medicine.",
"    </li>",
"    <li>",
"     Geriatrics Review Syllabus Supplement, 1993-1994 ed, Reuben DB, Yoshikawa TT, Besdine RW (Eds), American Geriatrics Society, New York 1993. p.172.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/139\">",
"      Sullivan DH. Impact of nutritional status on health outcomes of nursing home residents. J Am Geriatr Soc 1995; 43:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/140\">",
"      Reuben DB. Quality indicators for the care of undernutrition in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/141\">",
"      Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/142\">",
"      Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009; :CD000227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/143\">",
"      Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/144\">",
"      Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/145\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/146\">",
"      Mursu J, Robien K, Harnack LJ, et al. Dietary supplements and mortality rate in older women: the Iowa Women's Health Study. Arch Intern Med 2011; 171:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/147\">",
"      Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol 1989; 44:M112.",
"     </a>",
"    </li>",
"    <li>",
"     Tinetti MD. Falls. In: Geriatric Medicine, 2nd ed, Cassel CK, et al. (Eds), Springer-Verlag, New York 1990. p.528.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/149\">",
"      Chang JT, Ganz DA. Quality indicators for falls and mobility problems in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/150\">",
"      Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc 2001; 49:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/151\">",
"      Michael YL, Whitlock EP, Lin JS, et al. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/152\">",
"      Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/153\">",
"      Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA 2007; 297:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/154\">",
"      Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the \"get-up and go\" test. Arch Phys Med Rehabil 1986; 67:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/155\">",
"      Okumiya K, Matsubayashi K, Nakamura T, et al. The timed \"up &amp; go\" test is a useful predictor of falls in community-dwelling older people. J Am Geriatr Soc 1998; 46:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/156\">",
"      Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/157\">",
"      Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998; 46:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/158\">",
"      Lifford KL, Curhan GC, Hu FB, et al. Type 2 diabetes mellitus and risk of developing urinary incontinence. J Am Geriatr Soc 2005; 53:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/159\">",
"      Brandeis GH, Baumann MM, Hossain M, et al. The prevalence of potentially remediable urinary incontinence in frail older people: a study using the Minimum Data Set. J Am Geriatr Soc 1997; 45:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/160\">",
"      Roberts RO, Jacobsen SJ, Rhodes T, et al. Urinary incontinence in a community-based cohort: prevalence and healthcare-seeking. J Am Geriatr Soc 1998; 46:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/161\">",
"      Fung CH, Spencer B, Eslami M, Crandall C. Quality indicators for the screening and care of urinary incontinence in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/162\">",
"      Willlams CM. Using medications appropriately in older adults. Am Fam Physician 2002; 66:1917.",
"     </a>",
"    </li>",
"    <li>",
"     Essentials of Clinical Geriatrics, 4th ed., Kane R, Ouslander J, Abrass I (Eds), McGraw-Hill, New York 1999. p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/164\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/165\">",
"      Wang CC, Carr DB, Older Drivers Project. Older driver safety: a report from the older drivers project. J Am Geriatr Soc 2004; 52:143.",
"     </a>",
"    </li>",
"    <li>",
"     Physician's Guide to Assessing and Counseling Older Drivers. Available at: www.ama-assn.org/ama/pub/category/10791.html (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/167\">",
"      Reger MA, Welsh RK, Watson GS, et al. The relationship between neuropsychological functioning and driving ability in dementia: a meta-analysis. Neuropsychology 2004; 18:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/168\">",
"      Dubinsky RM, Stein AC, Lyons K. Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/169\">",
"      Centers for Disease Control and Prevention (CDC). Social support and health-related quality of life among older adults--Missouri, 2000. MMWR Morb Mortal Wkly Rep 2005; 54:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/170\">",
"      Lachs MS, Pillemer K. Elder abuse. Lancet 2004; 364:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/171\">",
"      Dong X, Simon M, Mendes de Leon C, et al. Elder self-neglect and abuse and mortality risk in a community-dwelling population. JAMA 2009; 302:517.",
"     </a>",
"    </li>",
"    <li>",
"     Aravanis S, Adelman R, Breckman R. Diagnostic and Treatment Guidelines on Elder Abuse and Neglect, American Medical Association, Chicago 1992.",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Healthy People 2010, conference edition. US Department of Health and Human Services, Washington, DC 2000. Available at: www.healthypeople.gov (Accessed on December 21, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/18/38186/abstract/174\">",
"      Wenger NS, Roth CP, Shekelle P, ACOVE Investigators. Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set. J Am Geriatr Soc 2007; 55 Suppl 2:S247.",
"     </a>",
"    </li>",
"    <li>",
"     www.americangeriatrics.org/products/positionpapers/index.shtml#1 (Accessed on January 15, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3017 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38186=[""].join("\n");
var outline_f37_18_38186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104693352\">",
"      GOALS OF CARE FOR OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF PREVENTIVE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tobacco use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aspirin for primary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tetanus vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Herpes zoster vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SECONDARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prostate cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2954742\">",
"      - Colorectal cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2954749\">",
"      - Breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2954756\">",
"      - Cervical cancer screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood pressure screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lipid screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TERTIARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Functional assessment and geriatric evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cognitive assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vision screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2634929\">",
"      - Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2634936\">",
"      - Multivitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Falls and mobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MEDICATION USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DRIVING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      FINANCIAL AND SOCIAL SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ELDER MISTREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ADVANCE DIRECTIVES AND HEALTH CARE PROXY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PATIENT RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3017|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?29/50/30496\" title=\"algorithm 1\">",
"      Prevention falls algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3017|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/35/5685\" title=\"figure 3\">",
"      Mini nutritional assesment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3017|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/40/21133\" title=\"table 1\">",
"      NNS to prevent cancer death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/52/846\" title=\"table 2\">",
"      Osteoporosis screening recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/20/12622\" title=\"table 3\">",
"      Screening frail older patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/30/38379\" title=\"table 4\">",
"      Fall risk assessment prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/47/5885\" title=\"table 5\">",
"      Get up and go test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/12/12494\" title=\"table 6\">",
"      Recommended scrn over 65 yrs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=related_link\">",
"      Age-related macular degeneration: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3385?source=related_link\">",
"      Approach to the evaluation of older drivers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43624?source=related_link\">",
"      Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17850?source=related_link\">",
"      Elder mistreatment: Abuse, neglect, and financial exploitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/12/31946?source=related_link\">",
"      Geriatric nutrition: Nutritional issues in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/54/867?source=related_link\">",
"      Patient information: Preventive healthcare for older adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9161?source=related_link\">",
"      Physical activity and exercise in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/58/41896?source=related_link\">",
"      Presbycusis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4552?source=related_link\">",
"      Safety and societal issues related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10760?source=related_link\">",
"      Treatment of dyslipidemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_18_38187="PARP inhibitors clinical development";
var content_f37_18_38187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A summary of representative PARP inhibitors in clinical development by route of administration and current clinical status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Company",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route of administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Olaparib (AZD2281)",
"       </td>",
"       <td>",
"        AstraZeneca/KuDOS",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        Phase I and II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Veliparib (ABT-888)",
"       </td>",
"       <td>",
"        Abbott",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        Phase I and II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AG014699",
"       </td>",
"       <td>",
"        Pfizer",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Phase I and II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MK482",
"       </td>",
"       <td>",
"        Merck",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        Phase I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        INO-1001",
"       </td>",
"       <td>",
"        Inotek",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Phase I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CEP9272",
"       </td>",
"       <td>",
"        Cephalon",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        Phase I",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous; PARP: Poly(ADP-ribose) polymerase.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anders C, Winer E, Ford J, et al. Poly(ADP-Ribose) Polymerase Inhibition: \"Targeted\" Therapy for Triple-Negative Breast Cancer. Clin Cancer Res 2010; 16:4702. Copyright &copy; 2010 American Association for Cancer Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38187=[""].join("\n");
var outline_f37_18_38187=null;
var title_f37_18_38188="Phenytoin poisoning - Rapid overview";
var content_f37_18_38188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phenytoin poisoning: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin is an anticonvulsant; fosphenytoin is a prodrug of phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurological signs are by far the most common manifestation of phenytoin overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid IV administration can cause hypotension, bradyarrhythmia, and possibly asystole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild poisoning: horizontal nystagmus, unsteady gait, worsening coordination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe poisoning: slurred speech; depressed mental status (possibly coma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory/diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Phenytoin toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obtain phenytoin serum concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obtain serum albumin if phenytoin concentration and clinical findings inconsistent; hypoalbuminemia predisposes to toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Routine testing in poisoned patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fingerstick glucose if mental status altered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acetaminophen and salicylate concentrations if possible suicide attempt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ECG to assess for poisoning by drugs that effect QRS or QTc intervals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pregnancy test in women of childbearing years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer activated charcoal (1 g/kg up to 50 g) for symptomatic acute ingestions, unless airway is not protected or other contraindications exist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer activated charcoal (1 g/kg up to 50 g) for asymptomatic patients who report significant ingestions if less than 1 to 2 hours after ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide supportive care as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with acute toxicity or moderate to severe symptoms from chronic toxicity should be hospitalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children may manifest signs of phenytoin toxicity at lower serum concentrations than adults and thus are more likely to require admission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with chronic toxicity may be discharged if they can ambulate safely and have someone to monitor them and assist with their activities of daily living until toxicity has resolved",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38188=[""].join("\n");
var outline_f37_18_38188=null;
var title_f37_18_38189="VE VCO2 and survival in HF";
var content_f37_18_38189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventilatory response to exercise predicts survival in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 299px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves for an 18 month follow-up of patients with heart failure show a significant increase in survival in patients with a normal ventilatory response to exercise compared to those with a VE/VCO2 ratio (the ratio of minute ventilation and carbon dioxide production) above 34.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Chua, TP, Ponikowski, P, Harrington, D, et al. J Am Coll Cardiol 1997; 29:1585.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38189=[""].join("\n");
var outline_f37_18_38189=null;
var title_f37_18_38190="Avulsionfracture of lateral malleolus";
var content_f37_18_38190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Avulsion fracture of the lateral malleolus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Seen on this x-ray is a transverse avulsion fracture of the lateral malleolus (yellow arrow)&nbsp;distal to the joint line. Such fractures are stable and may be treated like a severe ankle sprain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrice Eiff, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38190=[""].join("\n");
var outline_f37_18_38190=null;
var title_f37_18_38191="Enchondroma knee Xray";
var content_f37_18_38191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enchondroma of the proximal tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal radiograph of the knee shows stippled calcifications in the proximal tibial metaphysis, consistent with an enchondroma (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_18_38191=[""].join("\n");
var outline_f37_18_38191=null;
